Systematic Review of The Effect of High Pressure Ventilation Compared to Low Pressure Ventilation in Chronic Obstructive Pulmonary Disease Patients by Antoine-Pitterson, Pearlene Louisa
 Coventry University
MASTER OF SCIENCE BY RESEARCH
Systematic Review of The Effect of High Pressure Ventilation Compared to Low








Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of this thesis for personal non-commercial research or study
            • This thesis cannot be reproduced or quoted extensively from without first obtaining permission from the copyright holder(s)
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 23. Jun. 2021
Systematic Review of The Effect of 
 High Pressure Ventilation  
Compared to Low Pressure  
Ventilation in Chronic Obstructive  















   
  
ii | P a g e  
 
 
Systematic Review of the Effect of 
 High Pressure Ventilation  
Compared to Low Pressure  
Ventilation in Chronic Obstructive 








Supervisors Dr Amir Khan and 
Professor Derek Renshaw 
 
A thesis submitted is part of the university’s requirements for the degree of Master of 
Research Funded by HEE/NIHR 






Certificate of Ethical Approval  
Applicant:  
Pearlene Antoine-Pitterson  
  
Project Title:  
A systematic review to establish the effectiveness of high pressure Non -Invasive Ventilation 
compared to low pressure Non-invasive ventilation in Chronic Obstructive Pulmonary disorder.  
  
This is to certify that the above-named applicant has completed the Coventry University Ethical 




Date of approval:  
        18 January 2018  
  
Project Reference Number:  













Contents ................................................................................................................................................. v 
List of Tables .................................................................................................................................... ix 
Table of Figures ................................................................................................................................ x 
Glossary of Terms ................................................................................................................................ xi 
List of abbreviation ............................................................................................................................. xii 
Acknowledgements ............................................................................................................................ xv 
Scientific Abstract .............................................................................................................................. xvi 
Lay Summary ...................................................................................................................................... xix 
 Introduction .......................................................................................................................... 1 
1.1 Background ................................................................................................................................. 1 
1.1.1 What is COPD? ..................................................................................................................... 4 
1.1.2 Aetiology of COPD ............................................................................................................... 5 
1.1.3 Pathophysiology of COPD .................................................................................................. 6 
1.1.4 Chronic Bronchitis ............................................................................................................... 9 
1.1.5 Emphysema ........................................................................................................................ 10 
1.2 Diagnosis of COPD ................................................................................................................... 11 
1.2.1 Spirometry .......................................................................................................................... 11 
1.2.2 Effect on Quality of life ...................................................................................................... 16 
1.2.3 Chest Imaging .................................................................................................................... 17 
1.2.4 Exercise Tolerance ............................................................................................................ 18 
1.2.5 Management of COPD ....................................................................................................... 19 
1.3 Non-Invasive Ventilation (NIV) ................................................................................................. 21 
1.4 Domiciliary NIV .......................................................................................................................... 23 
1.5 Ventilator Settings .................................................................................................................... 25 
 Existing Systematic Reviews ........................................................................................... 27 
2.1.1 Why is this research important for patients?.................................................................. 31 
vi | P a g e  
 
 Aim ...................................................................................................................................... 37 
3.1 Philosophical Underpinnings .................................................................................................. 38 
3.2 PICO Components .................................................................................................................... 40 
 Methods............................................................................................................................................... 41 
 .............................................................................................................................................. 41 
4.1 Inclusion Criteria/Exclusion Criteria ....................................................................................... 41 
4.2 Study Design ............................................................................................................................. 41 
4.2.1 Population ........................................................................................................................... 41 
4.2.2 Intervention and Comparator ............................................................................................ 43 
4.3 Primary Outcomes .................................................................................................................... 43 
4.4 Secondary outcomes ................................................................................................................ 43 
4.5 Study Identification ................................................................................................................... 44 
4.5.1 Literature search ................................................................................................................ 44 
4.5.2 Screening and Selection ................................................................................................... 47 
4.5.3 Data extraction ................................................................................................................... 47 
4.5.4 Assessment of Risk of Bias .............................................................................................. 48 
4.5.5 Data Synthesis and Analysis ............................................................................................ 49 
4.5.6 Ethics................................................................................................................................... 51 
4.5.7 Data protection ................................................................................................................... 51 
4.5.8 Funding ............................................................................................................................... 51 
Characteristics of RCT’s .................................................................................................................... 53 
 Results and Findings ........................................................................................................ 54 
5.1 Summary of Results ................................................................................................................. 54 
5.2 Study Characteristics ............................................................................................................... 55 
5.2.1 Study population Participants .......................................................................................... 55 
5.2.2 Intervention and comparator ............................................................................................ 55 
5.2.3 Risk Of bias within studies ............................................................................................... 56 
5.3 Primary Outcome ...................................................................................................................... 57 
5.3.1 Effect of High IPAP compared to low IPAP on hypercapnia ......................................... 57 
5.3.2 Effect of high IPAP versus low IPAP on FEV1 ................................................................. 58 
vii | P a g e  
 
5.3.3 Effects of High-IPAP ventilation compared to Low-IPAP on exacerbation rates. ....... 60 
5.3.4 Effect on adherence. .......................................................................................................... 60 
5.4 Secondary outcomes ................................................................................................................ 60 
5.4.1 Effects on Health-related quality of life ........................................................................... 60 
5.4.2 Effects of high-IPAP compared to low-IPAP on exercise tolerance ............................. 61 
5.4.3 Reported adverse events .................................................................................................. 61 
 Discussion ......................................................................................................................... 63 
6.1 Summary findings ..................................................................................................................... 63 
6.2 Primary Outcomes .................................................................................................................... 63 
6.2.1 Arterial blood gases ........................................................................................................... 64 
6.2.2 Lung function ..................................................................................................................... 65 
6.2.3 Adherence ........................................................................................................................... 66 
6.3 Secondary Outcomes ............................................................................................................... 67 
6.3.1 Health related quality of life .............................................................................................. 67 
6.3.2 Exercise tolerance ............................................................................................................. 69 
6.3.3 Exacerbation ....................................................................................................................... 70 
6.3.4 Adverse Events .................................................................................................................. 70 
6.3.5 Generalisability .................................................................................................................. 72 
6.3.6 Sensitivity analysis ............................................................................................................ 72 
6.3.7 Limitations of the study ..................................................................................................... 73 
6.4 Future Works ............................................................................................................................. 76 
 Conclusion ......................................................................................................................... 78 
References ........................................................................................................................................... 79 
Appendices .......................................................................................................................................... xx 
Appendix 1 Studies Excluded at Full Text with Reason ............................................................. xx 
Appendix 2 Studies included in Meta-Analysis .......................................................................... xxi 
Appendix 3 Identified Systematic Reviews ................................................................................ xxii 
Appendix 4 Search Strategy ....................................................................................................... xxiii 
Appendix 5 Critical Appraisal frame work for Randomised Control Trials ............................. xxv 
Appendix 6 Data Extraction ...................................................................................................... xxxiv 
viii | P a g e  
 























ix | P a g e  
 
 
List of Tables 
Table 1 list of Abbreviations ...............................................................................................................xii 
Table 2 Clinical features of COPD (Albert, Spiro and Jett 2012) .................................................... 11 
Table 3 lung volumes and definitions (Wanger et al. 2005) ............................................................ 12 
Table 4 Category and characteristics of airflow limitation ............................................................. 15 
Table 5 Pharmacological management of COPD adapted from (Morrow 2018) ........................... 20 
Table 6 Non-Pharmacological Management of COPD ..................................................................... 20 
Table 7 Normal ABG Values and Type I RF and Type II RF adapted from (Davidson et al. 2016)
 .............................................................................................................................................................. 22 
Table 8 Physiological effects on NIV (Kallet 2015) .......................................................................... 22 
Table 9 Characteristics of Systematic reviews ................................................................................ 33 
Table 10 PICO components................................................................................................................ 40 
Table 11 Inclusion and exclusion of studies .................................................................................... 46 
Table 12 Database search and specialism ....................................................................................... 47 






x | P a g e  
 
Table of Figures  
Figure 1 Anatomy of the Lungs ........................................................................................................... 7 
Figure 2 Diagram of Medulla oblongata and, Respiratory control centre (Aminoff 2014) ............. 7 
Figure 3 Neural Control of Ventilation adapted from Spiro Albert Spiro and Jett (2012) .............. 8 
Figure 4 Volume-Time Spirograph of Lung Volumes and capacities ............................................ 13 
Figure 5 Volume Timed Curve of patients with COPD compared to normal (Talag and Wilcox 
2008) ..................................................................................................................................................... 14 
Figure 6 NIV interfaces (Nava, Navalesi and Gregoretti 2009) ....................................................... 24 
Figure 7 Flow Diagram depicting article selection .......................................................................... 52 
Figure 8:Randomised Control Trials included in Systematic Review ........................................... 57 
Figure 9 effect of High-IPAP Compared to Low-ipap on reduction of paCO2 .............................. 58 
Figure 10 Analysis on High Quality studies only ............................................................................ 58 
Figure 11: Effect of High IPAP compared to low IPAP on FEV1 Fixed effects meta-analysis ..... 59 






xi | P a g e  
 
Glossary of Terms  
 
 
Airflow obstruction a ratio of forced expiratory volume in one second to forced vital capacity which 
is < 0.7 (NICE 2010). 
Chronic Hypercapnic Respiratory Failure is indication of a raised partial pressure of carbon dioxide 
in the blood and a low concentration of oxygen in the blood, a normal pH is maintained, there is a high 
bicarbonate (Davidson et al. 2016). 
Chronic Obstructive Pulmonary Disease is a progressive lung disease characterized by airflow 
limitation (World Health Organisation 2017) 
Domiciliary non-invasive ventilation is the provision of non-invasive ventilation in a non-acute 
setting usually home or facility for long-term care. 
Dyspnoea is difficulty or labored breathing (Booth 2006, ES and HW 2001)  
Exacerbation A worsening state of symptoms from baseline, it is a natural course of the disease and 
includes a worsening of cough, dyspnoea, sputum production which results in a change of treatment. 
(M. W. Hess 2017)   
Hypercapnia A state of increase in Partial Pressure of Carbon dioxide in the blood above 6 Kpa 
(Davidson et al. 2016)  
Hypoxemia A state of low partial pressure of oxygen in the blood <8Kpa (Davidson et al. 2016) 
Non-Invasive Ventilation Mechanical ventilatory support as provided by a nasal mask or an oral nasal 
mask for the treatment of respiratory failure by maintain adequate gaseous exchange It is also referred 
to non- invasive positive pressure  
Stable COPD Referring to patients who are absent of symptoms for more than 4 weeks (NICE 2010) 
Standard Care/Usual Care A multidisciplinary approach to assessment and management of COPD, 
it is dependent on the stage of disease severity and includes pulmonary rehabilitation, Bronchodilation, 
with or without an inhaled cortico-steroid, mucolytic therapies and long-term oxygen therapy.(M. W. 
Hess 2017) 
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List of abbreviation  
 
Table 1 list of Abbreviations 
6 MWT  Six Minute Walk Test  
A&E Accident and Emergency 
AECOPD Acute Exacerbation COPD  
AHRF Acute Hypercapnic Respiratory Failure 
ANOVA Analysis of Variance  
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CI Confidence Interval 
CMH20 Centimetre of Water 
CO2 Carbon Dioxide 
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Scientific Abstract 
Title: Systematic Review of the Effect of High-Pressure Ventilation Compared to Low Pressure 
Ventilation in Chronic Obstructive Pulmonary Disease Patients. 
Background: Chronic Obstructive Lung disease (COPD) is a progressive lung condition made 
from a group of diseases. It is characterised by productive cough, dyspnoea and reduced 
exercise tolerance. Exacerbations often lead to hospital admission, reduced QOL (QOL), a 
decline in lung function (LF) and inefficient ventilation. The disease currently challenges the 
NHS. Hypercapnic respiratory failure is treated with Non-Invasive Ventilation (NIV), domiciliary 
NIV is provided by a nasal or face mask and improves gaseous exchange. Pressure pre-set 
mode involves setting an Inspiratory Positive Airway Pressure (IPAP), there is debate 
regarding support of high inspiratory pressure ventilation being the effective at reducing partial 
pressure of carbon dioxide (PaCO2), however despite this low inspiratory positive pressures 
are recorded in primary studies the results have suggested although an improvement in 
hypercapnia, results on clinical outcomes are not significant.  
Objective: This systematic review explored the effects of low-pressure ventilation compared 
to high pressure ventilation on Lung Function, Arterial Blood Gas, Quality Of life , exercise 
tolerance, adherence, and identify any risks in patients with COPD on domiciliary NIV.  
Methods 
Information Sources: Bibliographic databases were searched using keywords. CINHAL, 
MEDLINE, AMED via EBSCO Host and The Cochrane Library. Dates were search for English 
language studies between 1990 and 2017. Systematic reviews and meta-analysis reference 
lists were hand searched to assess for additional studies. 
Eligibility criteria: English language, randomised control trials. Excluded were observational 
studies, case studies, quasi experimental, narrative literature reviews and expert 
commentaries. Risk of bias was assessed using the Cochrane risk bias tool and the Critical 
xvii | P a g e  
      
Appraisal tool for RCT’s were used to critically appraise the methods completed by one 
reviewer.  
Results:  1613 articles were assessed following deduplication. Titles and abstracts were 
screened against inclusion and exclusion criteria. 3 randomised control crossover trials were 
included in the systematic review and meta-analysis. 48 patients were Identified in total a 
meta-analysis was completed on the following outcomes, PaCO2, FEV1 and HRQOL. There 
was no significant difference in the effect of High-IPAP compared to low-IPAP in the reduction 
of PaCO2 (p=0.19) with a mean difference of -0.39Kpa (95% CI [-0.96, 0.19]) and results were 
homogenous (I2=0%, p=0.83). There was no significant difference in High-IPAP compared to 
low-IPAP in FEV1 (p=0.49) (95% CI 0.38 [-0.69,1.45]). Results favoured high IPAP for 
improvement of HRQOL however there was no significant difference between the effect of 
High-IPAP compared to Low-IPAP with a mean difference of 0.11 (95%CI [-1.17,0.95] p=0.77) 
there was no heterogeneity in results (I2=0%, P=0.59). A meta-analysis could not be 
completed on adherence, exacerbation and exercise tolerance as there was little or no data 
provided to complete a meta-analysis.    
 
Conclusion: There was no significant difference in the effect of High-IPAP compared to low-
IPAP in the reduction of PaCO2, FEV1, adherence and HRQOL. Further studies are required 
to assess the effects on exacerbation, adverse effects and exercise tolerance as there was 
little or no data available on these outcomes to perform a meta-analysis and explore further. 
The study has implications as it demonstrates that randomised control trials are required to 
investigate the effect of pressure to ensure patients are provided with effective treatment of 
and improve patient outcomes.  
Registration PROSPERO CRD42018091592 
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Lay Summary 
  
Chronic Obstructive Pulmonary Disease (COPD) is  a group of diseases which, result in 
severe breathing difficulties and is often associated with of a history of prolonged smoking. 
Patients who suffer from COPD are, at risk of sudden worsening of symptoms, including 
excessive coughing and breathlessness and can often lead to a stay in hospital. As 
breathing is affected there is a build-up of a gas called Carbon Dioxide and more Oxygen is 
breathed out which, can be life threatening.  
Non-Invasive Ventilation (NIV) is a technique used for the treatment of people who suffer 
from severe breathing difficulties by providing a pressure on both a breath in and a breath 
out. This then allows air into the lungs to allow the body to remove carbon dioxide and 
breath in oxygen. At night this can often be a problem for patients with such severe 
breathing difficulty and may be offered NIV to use at home overnight, pressure settings for 
the machine are established by trained specialists in the field and often set due to clinical 
experience.   
 
It is not yet fully understood which pressure settings is most effective in removing carbon 
dioxide and preventing hospital admissions. This study has put together the available 
evidence to assess what settings are ideal used in patients with COPD and identifies what 
further research is needed.
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 Introduction 
 
The use of acute Non-Invasive Ventilation (NIV) has a well-established body of evidence for 
the treatment of acute hypercapnic respiratory failure (AHRF). AHRF is caused by 
respiratory disorders including Chronic Obstructive Pulmonary Disease (COPD), Obesity 
Hypoventilation Syndrome (OHS)/ Obstructive Sleep Apnoea (OSA), Chest Wall Deformities 
(CWD) and Neuromuscular disorders (NMD) all of which will cause ventilator insufficiency 
and is supported by up to date guidelines from the British Thoracic Society (BTS) (Davidson 
et al. 2016). Chronic respiratory disease is an area of medicine currently creating challenges 
in the NHS. COPD is the 3rd leading cause of death in the world and accounts for 251 million 
cases per year (World Health Organisation 2017). The Royal College of Physicians (2017) 
reported a rise in hospital admission secondary to acute exacerbation of COPD (AECOPD) 
from 2008-2014. 
 
1.1 Background  
Standard medical treatment of AECOPD includes inhaled therapy, oral steroids, antibiotics 
as indicated, pulmonary rehabilitation, long-term oxygen (LTOT) therapy if the patients fits 
within the guidelines for the prescription of Oxygen therapy for adults at home (Hardinge, 
Suntharalingam and Wilkinson 2015). For persistent Hypercapnic Respiratory Failure (HRF) 
the National Institute for Health and Clinical Excellence (NICE) (Gruffydd-Jones and 
Loveridge 2011) recommend nocturnal ventilation. It is recommended for its use to help 
improve quality of life (QOL) and one recent randomised control trials (RCT) demonstrated 
that there is a reduction in time to readmission following an acute exacerbation in patients as 
reported Murphy and Colleagues (2017), the authors investigated the effect of home NIV 
and home oxygen therapy compared to home oxygen therapy alone using a multicentre 
RCT. They hypothesised that the addition of home O2 to NIV would prologue the time to 
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readmission or death. Over 2000 participants were initially screened for their inclusion and 
exclusion criteria, and 116 patients were recruited. Random allocation was performed by a 
computer-generated system and they were either allocated into the NIV and home O2 or 
home O2 alone. Each patient had optimised standard medical therapy bronchodilator 
therapy, home O2 nebulised therapy antibiotics as indicated and oral steroids.  The main 
outcome was the time taken from random allocation to re-admission or death. Secondary 
outcomes included exacerbation frequency, Arterial Blood Gas (ABG), Health related quality 
of life (HRQOL) and mortality and participants were followed up at 3 months 6 months and 
12 months. Their results demonstrated there was a significant difference in time to 
readmission. The median time for readmission in the home NIV compared to home oxygen 
therapy was 4.3 months compared to 1.4 months in the group with home O2 alone. Its 
secondary outcome there was a significant reduction in PaCO2 at 12 months from 7.87Kpa to 
7.12Kpa in the home O2 and NIV group compared to home O2 alone. One possible 
explanation for this may be from using higher IPAP a median of 24CmH2O was used with 
patients in this study.  
 
In assessment of the quality of this research paper using the critical appraisal skills 
programme tool for RCTs (2017) there was an attempt at reducing bias, random allocation 
on a 1:1 basis ensuring the participants were matched at baseline and therefore minimising 
variables such as age and gender and ensuring random sequence generation therefore 
reducing selection bias and improving allocation concealment. The trial was single blinded 
as the researcher completing outcome measures was blinded to which treatment arm the 
participants were in and reducing performance bias, given the nature of the study it would 
not be possible for the participant to be blinded in the study however the investigator 
completing the outcome measure was blinded as to what treatment group the patient was in. 
There were strict inclusion criteria applied as patients were only included on the study 
diagnosis of COPD to ensure reduction of confounding variables with the absence of 
overlapping lung conditions such as Obesity Hypoventilation Syndrome (OHS), Obstructive 
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sleep Apnoea (OSA), uncontrolled Heart Failure, chest wall deformity (CWD) and 
neuromuscular disease (NMD). Overlapping lung conditions would be treated in a different 
approach and patients with NMD will respond to a volume assured NIV setting (Rabec et al. 
2011) and would have impacted the results equally it was to establish that the cause of their 
Type II RF was accredited to COPD and not an overlapping lung condition. The design was 
an RCT, therefore, a control group running parallel with an experimental group strengthens 
the results and establishes a cause and effect relationship (Bryman 2016). Both groups were 
optimally treated with standard care for COPD but, the experimental group were given an 
addition of NIV to long-term oxygen therefore their results demonstrate that any 
improvement was secondary to the intervention.  
 
The population of patients in this sample were representative of the population of COPD 
patients in the UK, average age 66 and gender with 54% of the participants are men and 
therefore results can be generalised to stable COPD patients. The trial demonstrated that 
NIV in addition to home O2 and standard therapy can have an effect of COPD and reduce 
hospital admissions. One of the possible reasons for the reduction of PaCO2 and time to 
readmission in COPD patients may have been secondary to the relatively High-IPAP used in 
patients and a limitation of the study as the authors have discussed is that there was no 
sham NIV group to compare to. High-IPAP are seen in patients with COPD who are 
hypercapnic by reducing dynamic hyperinflation and encouraging alveolar ventilation 
(Duiverman et al. 2016).  
 
Where Murphy’s and colleagues (2017) have demonstrated a significant clinical effect on the 
reduction of readmission following an exacerbation of COPD in conjunction with NIV 
systematic reviews (Becker et al. 2015, Dretzke et al.2015, Dretzke 2016 and Kolodziej et al. 
2007) have been unable to demonstrate this effect and there has been a paucity of 
evidence. One theoretical concept which may explain this may be because of the use of high 
Inspiratory Positive Airway Pressure (High-IPAP). High pressure ventilation has been used 
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in various trials (Dreher et al. 2010, Dreher et al. 2011, Duiverman et al. 2017) with the aim 
of maximally reducing the partial pressure of carbon dioxide in the blood (PaCO2). Windisch 
and colleagues (2005) discussed that for there to be greater improvement in physiological 
parameters in patients with Chronic Hypercapnic Failure (CHRF) receiving high-IPAP when 
compared with those receiving low-IPAP. They discuss an approach called High-Intensity 
Non-Invasive positive pressure ventilation (HI-NPPV) where a high-IPAP is combined with a 
high back up respiratory rate, subsequently there have been various surveys investigating 
this technique. The systematic review investigates, summarises and assimilates the 
available literature in the effectiveness of high-IPAP compared to low-IPAP in patients with 
CHRF caused by ventilatory insufficiency in COPD patient. 
 
1.1.1 What is COPD? 
 
COPD is a group of disease which is classified, diseases under the umbrella of COPD are 
Chronic Bronchitis, Emphysema and Asthma (Davidson et.al 2011, Alberto, Spiro and Jett 
2008). The World Health Organisation (WHO) define COPD as a “lung disease 
characterised by chronic obstruction of lung airflow that interferes with normal breathing and 
is not fully reversible” (WHO 2018) Characteristics of the disease include airflow limitation, 
persistent dyspnoea on physical activity, wheeze, chest tightness, cough and sputum 
production. The progression of the disease is not reversible and leads to both physiological 
decline and a decline in health-related QOL (HRQOL) for the patient and is a tremendous 
financial burden on the National Health Service (NHS) (Loveridge 2009). It has become one 
of the leading causes of disability and imposes a heavy burden on health care systems 
around the world (Vos, Flaxman and Naghavi 2012). Diagnosis is often accompanied by 
several co-morbidities including Ischemic heart disease, hypertension, diabetes and cancer 
which demonstrates an inflammatory process beyond the lungs as the disease progresses in 
severity (Hillas et al. 2015).
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COPD has been referred to in the past by different syntax such as chronic obstructive 
pulmonary disorder, chronic obstructive airway disease, chronic obstructive lung disease. 
Emphysema and chronic bronchitis are two conditions which can overlap and are referred to 
as COPD (Kumar 2009). The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
produced a classification system for the disease in 2001, in an editorial by Kerstjens (2004) 
he concludes that the disease is difficult to classify due to the lack of evidence base. 
Furthermore, Kerstjens explains that this is not related to what matters to the patients. From 
then there has been advances in quantitative evidence which, have contributed to a greater 
understanding of how the disease progresses and how the disease effects the patient health 
and well-being and at different stages of severity (Vogelmeier et al. 2017). Therefore, as a 
result it provides clinicians guidance as the diagnosis and management of COPD. 
 
1.1.2 Aetiology of COPD 
Tobacco smoking is one of the main causes on COPD and is thought that nearly 1 million 
people in the United Kingdom (UK) are living with the condition and it is a socioeconomic 
burden (Public Health England 2015). It poses a challenge to the NHS as it contributes to 
approximately 113000 accident and emergency admissions each year (Public Health 
England 2015). Although smoking is the primary cause of COPD the definition includes 
exposure to noxious stimulus and other risk factors associated with COPD include exposure 
to indoor pollutants, occupational exposure, outdoor air pollutants, genetic factors, age, 
gender, lung growth and development, Asthma, Chronic Bronchitis and socio economic 
factors (Vogelmeier et al. 2017)
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1.1.3 Pathophysiology of COPD 
 
Following prolonged exposure to noxious stimuli inflammatory changes to the alveolar arise 
(Chojnowski 2003) leading to a change in ventilation. Ventilation is a complex physiological 
mechanism which, in itself could take an entire thesis, control of ventilation and the 
respiratory muscles is controlled by an area of the brain called the medulla oblongata as can 
be seen in Figure 2 where the respiratory centres are located, (Dempsey and Smith 2014) 
and neural control allows for rhythmic ventilation Figure 2 and  Figure 3 depicts neural 
control of ventilation. Receptors in skeletal muscle and in the circulatory system detect 
chemical changes and induce a response for diaphragm and intercostal muscles to contract. 
There is a change in pressure gradient with a reduction of intrapulmonary pressure and an 
increase in extrapulmonary pressure, as air moves from a positive pressure gradient to a 
negative pressure gradient air then enters the lungs. 
  
A typical healthy lung is designed to be efficient in ventilation Figure 1 depicts this. The 
lungs are responsible for gaseous where oxygen (O2) enters the blood and carbon dioxide 
(CO2). Each lung is divided by horizontal fissures dividing them into lobes, pleural is a thin 
membrane: the visceral pleura is the inner layer lines the lung whilst parietal pleura is the 
outer membrane which is the outer layer and lines the chest wall. The two membranes 
adhere to each other and so within the pleura space is a small amount of fluid which acts as 
lubrication. During inspiration, surface tension is created, this is vital as it allows the alveoli 
to maximally inflate during inspiration (Albert, Spiro and Jett 2008). There are three lobes in 
the right lung and two lobes in the left lung. The trachea bifurcates into the right and left main 
bronchus and feeds into the corresponding lung. The bronchiole tree then divides into the 
bronchi of the lobes and further sub-divided into segmental bronchi with an estimation of 20-
25 generations which branch off and end with terminal bronchioles (Kumar 2009). They then 
give way to alveolar ducts, alveolar sacs and finally pulmonary alveolus where gaseous 
exchange occurs.
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Figure 1 Anatomy of the Lungs 
Schematic diagram of typical lungs, bronchiole tree and major structures (Rikxoor and Ginneken 
2013) 
Figure 2 Diagram of Medulla oblongata and, Respiratory control centre 
(Aminoff 2014) 
Key structures of the respiratory control centre and neural pathways taken in ventilation.   
DRG- Dorsal Respiratory Group PRG-Pontine Respiratory Group, VRG-Ventral respiratory 
group, NA-Nucleus Ambigus 
Some materials have been removed due to 3rd party copyright. The 
unabridged version can be viewed in Lancester Library - Coventry 
University.
Some materials have been removed due to 3rd party copyright. The 
unabridged version can be viewed in Lancester Library - Coventry University.
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Figure 3 Neural Control of Ventilation adapted from Spiro Albert Spiro and Jett (2012)  
 
The alveoli have several properties which make them efficient at gaseous exchange, a thin 
membrane, with a thickness measuring 1µm, and has a large capillary alveolar surface area 
(Petersson and Glenny 2014). Pneumocytes are alveolar cells and there are two which have 
important functions in gaseous exchange, Type I pneumocytes account for 90% of the 
alveolar surface, they are large squamous cells, which, are responsible for gaseous 
exchange into the blood stream by the process of osmosis. Type II pneumocytes function in 
two ways, by secreting surfactant, compromising of phospholipids and proteins and reduces 
surface tension within the alveoli. Type II pneumocytes are also able to divide therefore, 
when lung tissue is damaged it can increase in number due to cell division. The functions of 
these cell are vital for efficient gaseous exchange and Type I cells are susceptible to 
damage during exposure to noxious stimuli (Kumar 2009). A venous blood supply carries 
Some materials have been removed due to 3rd party copyright. The unabridged version 
can be viewed in Lancester Library - Coventry University.
 
9 | P a g e  
      
  
mixed venous blood with a low partial pressure of O2 (PaO2) and a higher partial pressure of 
CO2 (PaCO2). The difference in pressure gradient allows exchange of O2 across the 
membrane to enrich capillary blood flow with O2 and creating a higher pressure PaO2 in the 
capillaries and lower pressure PaCO2 in the capillaries (Petersson and Glenny 2014).  
 
1.1.4 Chronic Bronchitis  
 
The pathology of COPD results in an inefficiency in the gaseous exchange and subsequently 
respiratory failure. There is a rise in the number and size of mucus secreting goblet cells in 
the bronchial mucosa in both the large bronchi and bronchioles. Both acute and chronic 
inflammatory cells line the walls of the bronchioles and the epithelial layer can become 
thickened, excessive mucus secretions and thickened walls lead to a reduction in the lumen 
size of the small airways as well as infiltrate the epithelial cells with inflammatory mediator’s 
neutrophils and lymphocytes. A reduction in diameter then leads to airflow limitation. In the 
acute stages this damage is reversible if tobacco smoking is stopped, however the 
inflammation continues in later stages even when exposure is stopped. It is theorised that 
there is a change in the behaviour of T lymphocytes and plasma cells suggestive of a 
possible to immune response resulting in continued inflammatory response following 
smoking cessation in the later stages (Hogg 2006). As the disease progressed there is 
squamous cell metaplasia and fibrosing of the airway (Albert, Spiro and Jett 2012).  
 
In the acute stages of the disease small airways are affected however, as the disease 
progresses to a chronic stage there is destruction of lung parenchymal; a reduction in lung 
elasticity, air flow limitation; reduced alveolar ventilation; mucociliary escalator dysfunction ; 
increased secretion production and impaired gaseous exchange. Alpha1-antitrypsin is an 
enzyme inhibitor which, prevents against destruction of lung tissue however, exposure to 
noxious stimuli prevents the inhibitor from functioning and leads to the destruction of Type I 
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pneumocytes. Type II pneumocytes proliferate and differentiate into Type I pneumocytes 
and there is an adverse effect on surfactant leading to a loss of elastic recoil and dilatation of 
the lung tissue. 
1.1.5 Emphysema 
 
Emphysema is the permanent enlargement of airspaces, at the distal terminals of the 
bronchioles. The loss of structural integrity lead to dynamic hyperinflation and 
emphysematous changes appear in the lungs. Dilatation is concentrated to the larger 
bronchioles leaving the smaller airways relatively intact this is known and centrilobular or 
centri-acinar emphysema. In cases where there is complete destruction of the distal alveolar 
walls can lead to bullae as seen in pan-acinar emphysema (Faner et al. 2012). The changes 
lead to Ventilation Perfusion (V/Q) mismatching, this is a result of an increase mucous 
production causing plugging and due to the loss of elastic recoil and dynamic hyperinflation 
leads to impaired gaseous exchange. The impairment leads to inefficiency in gaseous 
exchange, retention of CO2 in the blood and a reduction of O2 in the blood. Following an 
exacerbation of COPD is severe cases it can lead to AHRF leading to hospitalisation and 
treatment with mechanical ventilation.
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Table 2 Clinical features of COPD (Albert, Spiro and Jett 2012) 
 
1.2 Diagnosis of COPD 
 
COPD is a group of conditions resulting in obstruction and measurable loss of lung volumes. 
GOLD (Vogelmeier et al. 2017) and National Institute for Care and Excellence (NICE 2010) 
define a clinical diagnosis. Symptoms reported are often dyspnoea, wheeze, cough 
productive of sputum and may be accompanied with a history of smoking of 20 pack years or 
greater. In patients who do not have a history of smoking an initial working diagnosis of 
Asthma due to the similarity in symptom presentation (Rennard 2012) in the absence  of a 
familiar history of COPD in which case an alternative diagnosis of Alpha1-antitrypsin 
Deficiency (Albert, Spiro and Jett 2012). Alpha1-antitrypsin deficiency is a genetic disorder, 
those born with the disease may not all suffer from respiratory disease; however, it poses a 
significant risk factor for developing COPD for those who smoke cigarettes (Vogelmeier et al. 
2017).  
1.2.1 Spirometry  
On report of a combination of symptoms patients are then subjected to spirometry. 
Spirometry is a pulmonary function test, it involves a forced expiratory volume (FEV) 
Some materials have been removed due to 3rd party copyright. The unabridged 
version can be viewed in Lancester Library - Coventry University.
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manoeuvre which assesses lung volumes, it is often the tool used to screen for patients for 
abnormalities in air flow and lung volumes. Pulmonary function tests allow for classification 
of stages of lung disease, however diagnosis is not made from pulmonary function tests 
alone. It is made in addition with the presence of clinical signs and symptoms as listed in 
Table 2.  
 
Lung volumes are described in the literature as early as the 1800’s (Wanger et al. 2005), 
lung volumes are influenced by height, weight, gender and age (Albert, Spiro and Jett 2012). 
Figure 4 demonstrates a spirograph measurement of lung volumes. It will also change in 
different, positions such as from supine to standing and these changes are normally due to 
the change in position of the diaphragm. Lung volumes are divided in a combination of lung 
capacities, Total lung capacity, Capacity is referred to as the combination of volumes which 
are subdivided, Table 3 lists the capacity and the subdivisions of volumes (Flesch and Dine 
2012). 






Some materials have been removed due to 3rd party copyright. The unabridged 
version can be viewed in Lancester Library - Coventry University.
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Figure 4 Volume-Time Spirograph of Lung Volumes and capacities 
(Taken from European Respiratory Society SERIES ‘‘ATS/ERS TASK FORCE: STANDARDISATION 
OF LUNG FUNCTION TESTING’’(Wanger et al. 2005) 
 
It is the pathogenesis of COPD which leads to responses that begin to form and all too 
familiar picture for patients who are admitted with exacerbation of COPD. The combined 
inflammatory responses lead to the increase in exacerbations. An exacerbation may be 
secondary to viral, bacterial, a combination of the two and in some cases, it may be 
unknown. Exacerbations often lead to hospital admissions and require treatment in the acute 
setting.  
 
As the disease progresses there are major developments of abnormalities to the alveolar 
caused by exposure to noxious particles or gases (Vogelmeier et al. 2017). Pulmonary 
Function testing is indicated following the reported symptoms, the degree of airflow 
obstruction is measured through spirometry, forced expiratory volume in 1 second (FEV1) 
and forced vital capacity (FVC) are measured. Spirometry has been used as a definitive 
mode of testing the degree of air flow limitation. It is an apparatus where by the patient is 
asked to blow long and hard through a machine and it measures the degree at   which, there 
is airflow limitation. There are defined normal spirometric measures which, can be 
Some materials have been removed due to 3rd party copyright. The unabridged version 
can be viewed in Lancester Library - Coventry University.
 
14 | P a g e  
      
  
comparable (Wanger et al. 2005) and deviations are used for diagnosis of COPD. There are 
additional methods to assess absolute lung volumes including plethysmography, nitrogen 
gas washout and radiographic imagery techniques. However, other methods are costly 
whereas, spirometry can be used in the primary care setting which, is a cost effective 
approach for assessment of LF and aid diagnosis and management in the primary care 
setting (Siafakas et al. 2018). 
FEV1 is indicative of the predisposition to LF decline, it is important that the measurement is 
taken once plateau is reached, the reading is normally taken three times to increase 
accuracy. Lung function (LF) is often affected by age, sex and height COPD in the elderly 
can over diagnosed as there is an expected reduction in FEV1/FVC of 0.65 to 0.70 
(Fernández-Villar, Soriano and López-Campos 2017). Over-diagnosis poses a potential 
implication of exposing patients to unnecessary pharmacological treatment, which is 
unnecessary and costly therefore imposing an extra financial burden. Overdiagnosis may 
happen due to elderly patients not demonstrating bronchodilator reversibility. Figure 5 
demonstrates a volume timed curve of patient with COPD compared to a patient who had 
normal LF. 
 
Figure 5 Volume Timed Curve of patients with COPD compared to normal 
(Talag and Wilcox 2008) 
Some materials have been removed due to 3rd party copyright. The unabridged version 
can be viewed in Lancester Library - Coventry University.
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As discussed earlier, an initial working diagnosis of Asthma may be concluded as a 
diagnosis by the GP however, spirometry can distinguish whether there is a degree of 
reversibility with bronchodilation which will distinguish between Asthma and COPD as well 
as identifying the degree of airflow limitation. There are four categories for classification of 
disease status. It has implications for reviewing the status of the disease and contributes to 
decisions on management of the disease. Table 4 depicts the categories and characteristics 
of airflow limitations. 
Table 4 Category and characteristics of airflow limitation 
Adapted from GOLD classification of airflow limitation in COPD (Vogelmeier et al. 2017). 
 
 
Arterial blood gases (ABG) are used to establish the degree of hypoxaemia and 
hypercapnia. As the severity of the disease progresses there is a disparity in ABG there is 
an increase PaCO2 and a reduction PaO2. As FEV1 falls below 50% there is greater disparity 
in ABG which, is due to V/Q mismatch (Petersson and Glenny 2014). ABG are greatly 
affected during exacerbation of COPD and overnight, sleep studies may be required to 
assess nocturnal hypoxia in patients who may have overlapping OHS/OSA. It important to 
note that sleep tests, for example overnight oximetry are not an indicator of disease severity. 
Some materials have been removed due to 3rd party copyright. The unabridged version 
can be viewed in Lancester Library - Coventry University.
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A respiratory muscle function test may be used as a way of assessing the strengths and 
function of the respiratory muscles (Albert, Spiro and Jett 2008). 
 
1.2.2 Effect on Quality of life  
As the disease progresses in severity there is a reduction HRQL, COPD is a leading cause 
of disability and is often accompanied by psychological implications such as anxiety and 
depression. The disease therefore not only affects their physiological health, but also their 
well-being. An assessment of the disability and psychological factors associated is important 
to establish a patient’s health status and it may be used a predictor of their prognosis in a 
study by Ahmed and colleagues (2016) they performed a cross sectional study on 124 
patients in India with a diagnosis of COPD. Patients were asked to perform spirometry and 
complete a St Georges Health Related QOL Questionnaire (SGRQ) (Weatherall et al. 2009), 
to assess the correlation between the severity of COPD and reduction in QOL. 
 
The authors demonstrated that there was a strong correlation between the severity of the 
disease and HRQOL scores. The more severe in stage of COPD the lower the QOL score, 
this study was a large study and completed in India and may not have matched participants 
with patients in Europe for example on socioeconomic status, health care provisions and it 
was also a small sample size. However, it is supported by a European (Jones et al. 2010) a 
study which, completed a large cross-sectional epidemiological study of over 1817 COPD 
patients who completed a St Georges Respiratory questionnaire COPD specific (SGRQ-C) 
(Meguro et al. 2007), Short form Health survey and the functional assessment of chronic 
illness therapy fatigue scale (FACIT). Characteristics of the patients included a mean FEV1 
of <56% and a mean age 65-year-old. Patients were excluded if they had an asthma or 
unstable cardiac disease. Information was collected on patient’s current medical 
management, ABG’s and medical history were collected, and the GOLD stage of COPD was 
calculated based on retrospective data on results . Spirometry was completed 6 months prior 
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to the survey. The authors found that the disease influences patient’s HRQOL even in the 
early stages of the disease. It highlights that there is a relationship between the decline of 
FEV1 and their HRQOL depending on the stage of the disease. 
 
It is important however to address the limitations of cross-sectional designs. Although the 
study design demonstrates a correlation between the stages of the disease and the effects 
on HRQOL, cross sectional designs provide only a snapshot of disease process at a single 
point in time and identifying relationships (Bryman 2016) however it is important to recognise 
that the design does not demonstrate cause and effect and is difficult to predict what will 
happen in the future as the disease process continues or if the results are sensitive to 
change in treatment as there is no follow up. It is also difficult to demonstrate if there was a 
reduction in HRQOL before diagnosis of COPD. In future studies assessing the impact of 
COPD on HRQOL there should be more robust designs with RCT design. 
 
1.2.3 Chest Imaging 
Other diagnostic measures include imaging chest X-ray (CXR) which, in isolation, is not a 
definitive diagnostic test, however, it can be used to distinguish and exclude other possible 
differential diagnosis. CXR are used to assess clinical features such as hyperinflation and a 
flattened diaphragm (Theerakittikul, Hatipoğlu and Aboussouan 2014). Computer 
Tomography (CT) is a diagnostic test preferred, to identify emphysematous changes and 
categorizing the stage of the disease and sensitive to changes in COPD (Kumar 2009). A CT 
can identify bulla, bulla is a large air space created secondary to destruction of the alveolar 
septa and dilatation of the alveoli. Bulla is often susceptible to spontaneous pneumothorax 
whereby air enters the pleural space (Boren 1959). 
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1.2.4 Exercise Tolerance  
In addition to imaging assessments of exercise capacity are also taken in patients with 
COPD. Progression of the disease leads to a reduction in exercise tolerance, increased 
dyspnoea, fatigue and respiratory muscle dysfunction all lead to reduce exercise capacity. 
Skeletal muscle wasting and, strength are both affected, specifically there is a reduction in 
the number of Type I muscle fibres which, are responsible for endurance and leads to a 
reduction in exercise capacity (Ambrosino 2002). From clinical experience it is the patient’s 
ability to achieve simple activities of daily living such as walking to the shops, will be limited 
by shortness of breath. Exercise capacity can be assessed in several ways using a variety of 
measures. It may include the 6-minute walk test (6MWT) which, is a standardised test which 
is used in the clinical setting to assesses a patient exercise capacity.  
As the disease progresses along with the patient’s V/Q mismatch, there is also a change in 
the efficiency of skeletal muscle to utilise O2 efficiently. The test involves the patient walking 
for 6 minutes, unassisted and the distance covered is then measured. The average distance 
walked is 500m for women and 580m for men (Talag and Wilcox 2008). The treatment itself 
evaluates physiological responses to of the cardiopulmonary vascular system, systemic 
response and skeletal metabolic responses. The test is more cost effective to complete 
compared to other methods of assessing exercise capacity such at cardiopulmonary 
exercise testing which involves specialist training and cost of equipment. 6MWT relies on the 
patients having to walk often a long a corridor measuring 30m in distance, it is relatively easy 
to perform and does not require training for the patient (American Thoracic Society 2002). 
Importantly this is a test of function and the patient’s ability to complete basic tasks of daily 
living such as walking make this an ideal outcome measure to assess functional ability and 
exercise tolerance. 
A sedentary patient is unlikely to reach maximal exercise capacity as this test allows patients 
to rest during the activity and does not require any additional equipment it therefore provides 
a more realistic idea of their level of exercise capacity to perform functional tasks (American 
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Thoracic Society 2002). There are many tests to measure exercise capacity in patients with 
diseases affecting pulmonary function, including cardiopulmonary exercise testing (CPET) 
and the shuttle walk test. CPET may be indicative when assessing the patient’s 
requirements for oxygen during activity. However, the 6MWT is practical to use in a variety 
of clinical settings both in the community and in an acute setting. As all tests are open to a 
degree of variability, completing the test in a controlled environment should be completed 
always to minimise sources which would affect the reliability of the results. The test is both 
reliable and sensitive to change and therefore an ideal measurement to review both 
prognosis and the effect of treatment (Sciurba et al. 2003). It is a combination of reported 
clinical symptoms and diagnostic approaches which lead the diagnosis of COPD. 
Categorizing the patients has implications for their management plan. 
 
1.2.5 Management of COPD 
 
Exacerbations are related to poor outcomes and a reduction in LF, acute exacerbation of 
COPD (AECOPD) leads to disability and its frequency is directly linked to the survival of 
patients with COPD (Gunen et al. 2005). The clinical features of pathophysiology are 
complex and therefore challenging for diagnosis and management. The severity has a direct 
relation to the management of the disease. GOLD classification of COPD has helped to 
guide management of patients, more recently there has been a greater transfer of treatment 
based on their phenotypical presentation. What GOLD have done more recently is ascertain 
diagnosis not only degree of airflow limitation but in conjunction with risk of exacerbation and 
their co-morbidities (Lange et al. 2016). The objective of this management is to reduce 
exacerbation of COPD and prevent hospital admissions and therefore reduce the burden on 
health care systems. Optimal management of patients with COPD will include both 
pharmacological management and non-pharmacological management strategies. Standard 
therapy based on GOLD and NICE guidelines for assessment and management of adult 
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COPD. Error! Reference source not found. and Error! Reference source not found. 
demonstrate pharmacological and non-pharmacological approaches to management of 
COPD. In this systematic review the focus will be on the use of domiciliary NIV and its role in 
the management of COPD. 






TABLE 6 NON-PHARMACOLOGICAL MANAGEMENT OF COPD  
(Morrow 2018) 
Some materials have been removed due to 3rd party copyright. The unabridged version 
can be viewed in Lancester Library - Coventry University.
Some materials have been removed due to 3rd party copyright. The unabridged version 
can be viewed in Lancester Library - Coventry University.
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1.3 Non-Invasive Ventilation (NIV) 
Mechanical ventilation was first mentioned as early as the 1800s where by the process of 
artificial respiration was introduced (Baker 1971). It is delivered by an oral nasal mask or 
nasal mask, NIV has been referred to as both Continuous Positive Airway pressure (CPAP) 
and Bi-level ventilation. CPAP is the delivery of one continuous pressure expiration and is 
used for the treatment on Type I respiratory failure (RF) where the primary problem is 
hypoxaemia. Bi -level ventilation provides two positive pressures on inhalation and 
exhalation is for the treatment of Type II RF. For this review NIV is referred to Bi-level 
ventilation. The principles are simple by delivering a pre-determined pressure on inspiration 
and expiration, it augments normal ventilation allowing for adequate gaseous exchange in 
patients with lung disease without the need for invasive techniques involving a tracheotomy 
or endotracheal rube. In an inefficient and ineffective ventilatory system, patients with COPD 
are at risk of AHRF because of a combination of pathophysiological changes. The 
physiological changes lead to inefficient ventilation a reduction in tidal volume and therefore 
an increase in PaCO2 and a reduction in PaO2, this is demonstrated following an ABG and is 
called Type II respiratory failure (RF).  
 
The indication of NIV in an acute clinical setting will include a diagnosis of COPD or lung 
condition with the AHRF as determined by ABG Table 7. Patients should be in single system 
organ failure and have complete a course of 1 hour maximum medical management 
unsuccessfully before NIV is initiated (Davidson et al. 2016).  
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Table 7 Normal ABG Values and Type I RF and Type II RF adapted from 
(Davidson et al. 2016) 
As mentioned the aim of providing optimal therapy for patients with COPD is to reduce the 
incidence of exacerbations. NIV is used in the acute setting and has physiological effects 
because of IPAP and EPAP, which,  help to reverse Type II RF Table 8 summarises the 
physiological effects of NIV to improve ventilation and reverse hypercapnic respiratory 
failure. 
Table 8 Physiological effects on NIV (Kallet 2015) 
Some materials have been removed due to 3rd party copyright. The unabridged version 
can be viewed in Lancester Library - Coventry University.
Some materials have been removed due to 3rd party copyright. The unabridged 
version can be viewed in Lancester Library - Coventry University.
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1.4 Domiciliary NIV 
 
Domiciliary NIV has many terms such as home NIV, long-term NIV and nocturnal NIV to 
name a few but the objective of long-term NIV in patients with COPD is to reduce hospital 
admissions and improve the patients QOL. The pathogenesis of COPD leads to an increase 
in PaCO2 and a reduction of PaO2 which becomes chronic hypercapnic respiratory failure 
(CHRF). Nocturnal hypercapnia occurs following hypoventilation, during sleep there are 
several physiological mechanisms which would not affect a normal health individual 
however, COPD patients who have an inefficient ventilatory system are at risk of reduction in 
respiratory function. During sleep there is a change of posture therefore putting the 
diaphragm at a mechanical disadvantage, there is increased upper airway resistance 
therefore a degree of obstruction, most importantly there is a reduction in ventilatory drive 
(Maranetra and Pain 1974). Peripheral and central chemo receptors detect a reduction in 
PaO2 and an increase in PaCO2 and hydrogen ions which result in an increase drive to 
breath. This stimulation is thought to be altered in COPD patients and because of V/Q 
mismatch and the Haldane effect by where haemoglobin has a great affinity to CO2 and as 
minute ventilation is reduced in COPD patients there is greater retention of CO2 (Abdo and 
Heunks 2012) therefore hypercapnia occurs. During sleep the process is exacerbated and 
as COPD progresses it leads to derangement of ABG and hospital admissions. 
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From Top Left to bottom right names of interfaces. Nasal Mask, Nasal Pillows, Oropharyngeal 
mask, Hybrid, Hybrid without nasal pillows, Full face mask, Hood  
 
Long-term nocturnal NIV can be beneficial in reducing PaCO2 in the blood, by providing a 
more efficient and effective ventilation mechanism to reduce PaCO2. Indications of long-term 
NIV are still poorly understood, there has been a recent survey completed to assess the 
indications and review practices among physicians looking after severe COPD patients 
(Crimi et al. 2016). Their web-based survey demonstrated that clinicians prescribe NIV with 
the perceived benefit of reducing hospital admissions, increasing patients QOL, reduce 
dyspnoea, improve exercise tolerance (ET) and LF. One other outcome that was anticipated 
was an increase in survival in patients in COPD. Indications for NIV however appeared 
diverse, the authors ranked in order of importance what the participants view was that on 
indicators for long-term NIV 3> admissions for HRF, failure to wean from NIV, PaCO2 of 
above 7.33Kpa, a PaCO2 6kpa > + hospital admissions, a PaCO2 6kpa > with desaturations, 
increased PaCO2 with hypoxia. The main indication was severe hypercapnia with an inability 
to wean off NIV. This again is not a definitive indication for long-term NIV criteria the survey 
had a 42% response rate and the study was conducted across Europe to reflect the 
geographical variations in NIV prescription. The study was conducted using a purposive 
Figure 6 NIV interfaces (Nava, Navalesi and Gregoretti 2009) 
Some materials have been removed due to 3rd party copyright. The unabridged 
version can be viewed in Lancester Library - Coventry University.
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sampling strategy, in which the 15 physicians shared details of their colleagues contact 
details to distribute the survey, this sample technique enabled them to be put into contact 
with experts in the field who would be able to answer the question the research question 
proposed (Parahoo 2016). 
 
The survey by Crimi and colleagues (2016) highlight the varying practices across Europe, 
however the survey does much more by highlighting the differences in practice between 
approaches taken in NIV prescription. In contrast the survey does not show that there is 
benefit but more that it is a perceived benefit. The survey is based on expert and opinion and 
there is little known as to what pressures are best used for the prescription of domiciliary NIV 
and it is often left to the clinician’s expertise as to what is the optimum pressure setting to 
use and therefore remains the question of what is the best settings to use in patients with 
COPD? The survey contributes to the theoretical concept of why practitioners clinically 
reason the prescription of domiciliary NIV to a population that systematic reviews (SR) and 
meta-analysis have demonstrated that there is no significant benefit for the treatment 
HRQOL and exacerbations compared to standard treatment (Becker et al. 2015, Dretzke et 
al. 2015, Dretzke et al. 2016, Kolodziej et al. 2007 Table 9). There is little definitive guidance 
as to the indications of NIV however the survey was able to highlight common practices 
amounts different clinicians, the author asked questions to investigated practices in ventilator 
modes, settings and interfaces Figure 6 refers to the range of interfaces for patients.  
 
1.5 Ventilator Settings  
 
Different modes of ventilation are used in the clinical setting. Modes include pressure pre-set 
and volume assured, each may have different names dependent on their manufacturers 
branding and each setting or mode of ventilation may be used dependent on the 
presentations (Rabec et al. 2011) as new brands and developments in NIV continue there 
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have been the introduction of hybrid mode integrating volume with a predetermined 
parameter and back up rate with the patients spontaneous breath (Ekkernkamp et al. 2014) 
with each method has advantages and disadvantages. Volume assured (VA) delivers a fixed 
volume during a given time and is guided by set parameters. The idea is that predetermined 
volume and flow rate to encourage ventilation. However airway pressure is determined by 
airway resistance and compliance this is not considered and therefore cannot guarantee the 
patients tidal volume and there is no attempt at compensation for leak (Rabec et al. 2011).  
Pressure pre-set generates airflow at a pre-determined pressure and therefore to maintain a 
pressure support. It can auto adjust to maintain a constant airway pressure support by 
maintain flow and therefore attempts to adjust if there is a significant leak of air at the mask. 
There are many advantages and disadvantages to each mode, pre-set pressure modes are 
increase the risk of damage to the airways called barotrauma. This Systematic review will 
focus on domiciliary NIV and management of COPD. 
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  Existing Systematic Reviews  
 
Over the last 20 years there has been a growth of research into the effectiveness of NIV on 
patients with CHRF. Large Systematic Reviews (SR) and meta-analysis have investigated 
the effectiveness of NIV compared to standard treatment Table 9 lists the characteristics of 
the systematic reviews. The results have not identified that NIV is superior treatment 
compared to standard therapy, yet the NIV is still a treatment choice for clinicians (Crimi et 
al. 2016) studies establishing the effect of NIV have used what can be considered as low-
pressure ventilation and therefore have had a minimal effect on hypercapnia (Windisch et al. 
2002).  
 
In a systematic review by Kolodziej  and colleagues (2007) in, which authors searched 
publications from 2001-2002 using both bibliographic databases and hand searching of 
journals they located 15 publications investigating the effect of NIV in severe COPD. The 
authors included both RCT’s and Non RCTs, to examine the effect on respiratory function 
and health related outcomes such as dyspnoea, functional status HRQOL, exercise 
tolerance, morbidity and mortality. The authors narratively analysed comparator 
interventions and identified NIV compared physical activity, LTOT, and other modes of 
ventilation. In addition, the authors compared the length of follow up each trial that was 
conducted and narratively assessed and noted that there was great variation varying from 2 
days to 5 years. They completed a meta-analysis on non RCTs comparing NIV to other 
treatments, there was a favourable effect on respiratory function including an improvement 
of PaO2 and a reduction of PaCO2. On appraisal of the review, the search was conducted 
between 2001 and 2003 there is no specific reasoning of why only over a 2-year period, in 
doing so the search year automatically rules out studies completed before which may have 
answered the question. The search identified 308 studies in total to be screened against 
inclusion and exclusion criteria. They had conducted a thorough search by hand searching 
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as well as electronic database searches therefore as recommended by the Cochrane 
collaboration (Higgins 2011) able to identify studies which may not have been identified by a 
database search alone (Cochrane Library 2017). Assessment of quality was completed by 
two separate reviews and therefore minimising the potential for bias by two people 
completing quality assessment (Parahoo 2014). As a result, there is minimised potential of 
selecting studies which would be more favourable to answer the question. 
 
There were no studies identified from the authors search which investigated the effect of 
different NIV settings although this was not the primary aim as part of their systematic 
review, which was to compare NIV to different types of NIV, this may have been due to the 
limitation in search year. However, the findings from this review are further supported by two 
other SR conducted investigating the effect of NIV compared to standard treatment. Two SR 
completed in 2015 were completed examining the cost effectiveness of Domiciliary NIV 
compared to standard care in the treatment of patients with Domiciliary NIV by Dretzke and 
colleagues (2015) and Becker and colleagues (2015) both SR were Health Technology 
Assessments. Dretzke and colleagues (2015) completed in England whilst Becker and 
colleagues in Sweden. In a systematic review by Becker (2015) they aimed to answer two 
primary questions what the effect of NIV is compared to standard treatment and what is the 
effect of High intensity NIV (Hi-NPPV) compared to Low intensity NIV (LI-NPPV) on clinical 
outcomes and health related QOL outcomes. Their search included years 1980-2015 and 
bibliographic databases were searched including MEDLINE, PubMed, EMBASE, Cochrane 
library and HTA-databases, terms search were key words and Medical Subject Headings 
(MeSH). The title and abstracts were screened independently by two reviewers and 
discrepancies were discussed and resolved by third party. Full text articles were critically 
appraised by two independent reviewers against Grading Recommendation Assessment, 
Development and Evaluation (GRADE) system and a Swedish critical appraisal checklist as 
provided by the Swedish Council of Health Technology Assessment was used to assess the 
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quality of the paper and disagreements were resolved by consensus. In total 14 articles were 
included in the review of RCTs, Non RCTs and SR. Some of the studies identified had low 
certainty in assessment due to lack of blinding or no control group therefore increasing the 
risk of blinding in results. Including low quality publications, the results will affect the quality 
of the quality of the systematic review overall (Higgins 2008). Their results demonstrated that 
NIV compared to standard care may reduce mortality in COPD patients, improve HRQOL 
and improve dyspnoea with low certainty of evidence. There is little or no effect on patients 
who receive NIV compared to standard care on sleep quality, hospital admissions and 
exercise tolerance this is again with a low certainty of evidence.   
 
Their second question assessed the effect of HI-NPPV compared to LI-NPPV, their search 
identified only one randomised cross over study completed by (Dreher et al. 2010) which, 
investigated the effect and therefore quality of recommendations based on this review are of 
extremely low certainty. As only one study identified there was no report on mortality and 
readmission rate. There is uncertainty in the effect on sleep quality, exercise tolerance, 
dyspnoea and reduction of PaCO2. Due to the limitation in evidence it is difficult to complete 
a conclusion from the review this review alone and therefore there is a need for further 
review and examination of the effect of pressure settings in NIV and this is further supported 
by Dretzke and colleagues systematic review and meta-analysis of the cost effectiveness of 
NIV compared to standard care in patients with end stage COPD.  
 
Completed in the same year they searched electronic bibliographic databases between 
1990-2014 and using a Markov Decision Model , which is a method of evaluating the 
healthcare cost in long-term conditions is varying disease states (Sculpher, Fenwick and 
Claxton 2000) and is a valid instrument to be used in this condition. In a study which 
identified 158 articles the results from the economic analysis demonstrated that there was a 
reduced risk on readmission in patients receiving NIV compared to those receiving standard 
treatment and this was supported by earlier economic analysis completed by Tuggey and 
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colleagues (2003), it is a disease specific systematic review however it may be possible to 
evaluate outcomes in long-term respiratory conditions such as cystic fibrosis where 
domiciliary NIV is used. In this study it demonstrated a wide range of NIV modes and 
pressure settings used in a variety of studies, from volume assured to higher pressure 
ventilation and prompts the question of what the optimum pressure or settings are used to 
have a greater patient benefit. As a sub category the authors investigated the effect of 
different setting of NIV in patients with end stage COPD. However, from their results they 
identified 3 studies which investigated the use of settings in NIV, due to the limit in studies 
identified and the heterogeneity in the outcome measures, length of intervention, numbers 
and study design the authors were unable to make any conclusions regarding the effect of 
pressure on NIV. Compared to Becker and colleagues ( 2015) this was a much larger review 
with no limitation on language and was able to identify more studies based in inclusion and 
exclusion criteria. The review was completed by more than one reviewer and minimising 
research bias. Studies were only included if they were of low risk bias and therefore this 
strengthens the quality of the systematic review. Dreher et al. (2010) was identified in both 
studies investigating the effect of pressure and therefore demonstrates at the time that there 
is further research needed to establish and effect. 
 
Importantly it must be noted that the search strategy for Dretzke and colleagues (2015) and 
(Kolodziej et al. 2007) was not directly designed to identify studies to analyse the effect of 
pressure on outcomes for patients with COPD, as it was not the primary aim of the original 
study but a sub-category. Becker and colleagues (2015) investigated the effect of non-
invasive ventilation on clinical outcomes and directly asked the question in relation to NIV 
settings as their second and the effect of Hi-NPPV compared to LINPPV on clinical 
outcomes, although the search strategy designed to suit the first objective. As a result, 
studies may have been missed which did not directly address the question. To address the 
question of the effect of High-IPAP compared to low-IPAP on patients with COPD receiving 
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domiciliary NIV a SR search strategy must be designed to address the question.  
Windisch and colleagues have (2002) have discussed the use of High-IPAP with high back 
up rates with the aim of maximally reducing PaCO2 and aiming for normocapnia in patients 
with CHRF. Higher inspiratory pressures are thought to have a greater effect on VT by 
increasing inspiratory volumes and reducing leak from the NIV mask and improving 
compliance with patients COPD patients (Dreher et al. 2010). The physiological benefits are 
thought to be an improvement in FEV1, exercise tolerance and QOL, (Duiverman et al. 
2016). Budweiser and colleagues (2005) examined the effect of home ventilation on patients 
with COPD their objectives were to investigate the effect of long-term ventilation on patients 
with COPD. NIV works by reducing dynamic dead space to improve alveolar ventilation, their 
study used retrospective data of 42 patients using plethysmography which is an accurate 
way of measuring TLC, IC, RV. Inspiratory lung capacity was calculated as the difference 
between TLC and intra thoracic gas volume. NIV was set using either a face mask and 
patients were reviewed at 6 and 12-month follow ups as inpatients. The median daily 
application time was recorded to assess compliance and 6.1 hours and the mean IPAP 
was19.9CMH20. The authors demonstrated that there was a reduction in lung capacity at 
different time periods. This was a retrospective exploratory design and as there is no control 
group there are other variable to consider in the reduction hyperventilation it does not 
demonstrate causality. There was a strong correlation between High-IPAP and reduction of 
PaCO2, however all patients were treated with standard pharmacological treatment including 
the use of bronchodilators and steroids which may have contributed to the reduction in at 
this is standard therapy used in the treatment of patients with COPD (Vogelmeier et al. 
2017). 
 
2.1.1 Why is this research important for patients? 
From reviewing published literature there have been several questions raised regarding the 
effects positive pressure settings, Low-IPAP settings are thought to more effective in 
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reducing dyspnoea and maybe more favourable with synchrony of the patients breathing. 
Equally low-IPAP are thought to be less effective at reducing PaCo2 in patients with CHRF 
(Windisch et al. 2002). In both larger SR (Becker et al. 2015, Dretzke et al. 2015), they have 
been unable to conclude as to the most effective pressure settings to use in patients with 
COPD. A further study was conducted Dretzke and colleagues (2016) thought to be part of 
the original review in 2015. In which the results demonstrated similar findings to that of 
Dretzke and colleagues (2015) when investigating the clinical effect of domiciliary NIV in 
patients with COPD, therefore calling for further research in the area to address this issue.   
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SR to date, investigating the effect NIV in addition of usual care have demonstrated there is 
no added benefit in terms on QOL and hospital admissions compared to usual care alone. It 
is believed that this may be due to patients not receiving adequate ventilator pressures 
(Windisch et al. 2002). However, there is published evidence demonstrating a greater effect 
on hypercapnia, reduced time to readmission and improvement in exercise tolerance. There 
is much published evidence on the effects of acute NIV on AHRF and recent RCT’s 
evaluating the long-term benefits of NIV (Murphy et al. 2017). There is greater understanding 
into how NIV can have an impact on patients with COPD in AHRF. After several admissions 
for AHRF patients are considered for domiciliary NIV. There is published evidence in the 
field of acute NIV in AHRF which, suggest pressure settings to start with to allow for effective 
and efficient ventilation of patients and to reverse AHRF (Davidson et al. 2016). 
 
SR have addressed the effect of domiciliary NIV compared to standard treatment for patients 
with COPD however investigating the effect of different pressures on NIV has not been 
successful due to the paucity of evidence. The reviews have attempted to answer the 
question in sub studies in their reviews however it given that it was not their primary aim it 
may have been that their search strategies were not designed to find and identify all studies 
to answer the question. The objective from this SR is to review the effect of High-IPAP on 
ABG’s, LF, exercise tolerance, QOL and hospital admissions. The overall aim of the 
systematic review is to collate data from existing RCTs critically appraising the evidence and 
synthesising the finding to add to the growing body of evidence to provide a deeper 
understanding of how long-term ventilation benefits the patients and to identify if there are 
any potential risk to the patient. Greater understanding of the effects of different pressure 
settings it will help to promote admission free survival of patients with COPD, in tern it will 
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provide insight into what further research is required in the future to improve the provision of 
patient care.   
3.1 Philosophical Underpinnings 
 
 
Reaching new conclusion is research requires the application of a systematic and scientific 
approach, and so in intervention studies, understanding effectiveness of treatment 
modalities is important to demonstrate how efficient and effective a treatment modality is. 
More importantly in the NHS is the need to demonstrate that treatment modalities are 
sustainable in the long-term and much health and social care research is geared towards 
more of a creation of sustainable healthcare system in which to provide safe care to patients 
and the public (Department Of Health and Social Care 2015). Practitioners are bound, by 
their professional registration to provide evidence-based practice (EBP) however it is often 
with challenges of clinical practice in which, we require the need to put research into practice 
and a systematic search of available literature is required to form a solution or treatment 
which is supported by strong evidence. In this case the research question was formed based 
on the need to understand how to make home ventilation for patients safe, effective and 
efficient.  
 
It is a challenge that healthcare practitioners face daily however, to gain understanding a 
systematic approach is needed to assess the truth behind results. After an important clinical 
question is asked there is systematic search of available and relevant evidence, critically 
reviewing the evidence for systematic bias and integrating evidence with clinical knowledge 
and then constructing an informed judgement as to the effect of a specific treatment. The 
search for knowledge and truth is often conducted according to a paradigm that is in line with 
the researchers worldview (Bryman 2016, Polit 2014). In quantitative studies there is both 
experimental which, is aimed at understanding the way in which an intervention works and 
observational where data is collected overtime without the introduction of an intervention 
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(Polit 2014). Quantitative research derives from a postpositivist paradigm and so there is the 
belief that human phenomenon can be objectified and such thought to be more rational and 
scientific than its counterpart of constructivism (Creswell 2014) As such is there is the belief 
that there is cause and effect, for example a patient develops COPD there is the scientific 
explanation is that the patient has had exposure to noxious stimuli. A positivist theorist would 
seek to find an answer by using deductive approaches (Parahoo 2014), in such isolating 
variables and introducing a control and therefore an attempt to minimise systematic bias 
(Hammersley 1996). In so the theory is in line with the ontological approach in which nature 
is explained by cause and effect relationships. Observational studies and experimental 
studies gather empirical data in a systematic and measurable way in which to explain a 
phenomenon. Their epistemological approach is to limit variables by ensuring control on 
measures is an attempt for the researcher to detach themselves from the world around them 
and minimise researcher bias.  
 
SR are not empirical designs but seek to review empirical research to gather data. The 
nature of this review is to establish the effectiveness of a treatment modality. A systematic 
review of empirical evidence follows the paradigm of a positivists view as a systematic 
approach is applied to gather evidence to explain a phenomenon by assimilate and gain 
coherence (R. D. Riley, Higgins and Deeks 2011). From an ontological standing the 
research assesses which intervention is more effective in patients with COPD. From an 
epistemological view point, a systematic search of the literature and data collection from 
RCTs pool secondary data to assimilate knowledge to contribute to a greater understanding 
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3.2 PICO Components  
 
Table 10 PICO components 
Population  
 
Adult patients 18 > years or over with COPD with severe airflow 
limitation and as confirmed by lung function tests FEV/FVC ratio <70%.  
Patients must be stable who have required long-term NIV. Stable COPD 
would be defined as in the absence of acidosis on ABG, must not be 
receiving treatment as an inpatient for AHRF in an intensive care unit 
but it will include patients who have received NIV post hospitalisation 
for long-term management.  
Intervention  NIV in pre-set pressure, it is not to include the all mode of NIV such as 
volume assured mode or hybrid modes such as intelligent volume assured.  
In this context as the objective is to review patients on long-term oxygen the 
term domiciliary is referred to as treatment which includes long-term 
nocturnal ventilation. It is absent of the use of NIV delivered by 
tracheostomy.  
 
High-IPAP will include variations such as high intensity but this is to consider 
patients on a pressure pre-set mode of ventilation. 
After a review of the literature there is no absolute definition of what high 
pressure is. However, based on previous studies the definition for this review 
will focus on an IPAP ≥ 20CMH2O is to be considered as higher-pressure 
ventilation. 
Comparator Low-IPAP will be defined as patients receiving NIV in pre-set pressure mode 
and receiving a pre-set pressure of ≤19CMH2O  
Outcome To gain a clear clinical picture of the effects of NIV, the following outcomes 
will be considered. Primary outcomes that will be assessed in this systematic 
review will include data on Lung function, the effect on arterial blood gases 
(PaCO2 and PaO2), FEV1 and FVC, compliance as reported by number of 
hours used and recorded on NIV. Secondary Outcomes include reports on 
QOL, exercise capacity, report of any adverse effects recorded.  










4.1  Inclusion Criteria/Exclusion Criteria 
To identify studies which, will be suitable to answering the research question as broken 
down in Table 10, studies were assessed against a set of inclusion and exclusion criteria. 
RCT’s have definitive inclusion and exclusion criteria of patients to include in an empirical 
study by assigning inclusion and exclusion criteria and ensures that studies identified are 
appropriate to answer the research question (Charrois 2015). It is important to plan and 
define the outcomes that are required to review the question a set of inclusion and exclusion 
criteria is required to allow boundaries to be set of the review (Higgins 2011, Parahoo 2014) 
Table 11 demonstrates the criteria from which studies were selected based on eligibility 
criteria to address the outcomes of the systematic review. 
 
4.2 Study Design  
 
RCT’s and SR were included the study designs are recognised as the top of the hierarchy of 
evidence, and this is due to the rigor at which they are designed to (Bryman 2016, Parahoo 
2014). RCT’s by design aim to eliminate confounding variables by providing a control group 
and attempts to minimise chance and establish that the intervention is the cause of any 
difference in results between groups (Polit 2014).  SR were identified to hand search and 
identify further studies which may be relevant the systematic review objectives. 
 
4.2.1 Population  
For the outcomes of this review a search strategy was designed to be inclusive of the 
population, of stable hypercapnic COPD patients and intervention NIV. It is mentioned earlier 
that there is documentation in the literature of NIV from the 1929 in which, Drinker and Shaw 
(Drinker and Shaw 1929) discuss the use of an artificial respiration using a treatment 
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modality providing insufflation, however the routine use of NIV both in AHRF and long- term 
use of NIV has been in place since the 1990’s (Elliott et al. 1990) it is for this reason that 
searches were designed to be inclusive of the years from January 1990 to December 2017. 
Both English language title and abstracts were scanned however only English language 
studies were included for assessment. This was because there was no translator on the 
team, but studies were not limited to country. 
 
Studies were included adults 18≥ years who were diagnosed had a diagnosis of COPD with 
a GOLD standard group III-IV with and FEV1 ≤ 0.7. NIV is recommended for patients who 
are in the later stages of the diseases, are given with patients who are frequent exacerbators 
3 or more admissions requiring the treatment of NIV for AHRF (Crimi et al. 2016).  It is 
recognised that patients admitted for AHRF occur in the later stages of the disease(Riley 
2013). Patients must be stable as defined as the absence of a cough and production of 
purulent sputum, no hospital admissions in the last 4 weeks to 3 months requiring NIV or 
intubation (Vogelmeier et al. 2017). 
 
Studies were excluded if the population studied were diagnosed with OSA/OHS, NMD, 
unstable heart failure, pneumonia, pulmonary oedema or CWD. The reason for this is ensure 
that the population studies had a pure diagnosis of COPD which was causing HRF, Rebec 
and colleagues (Rabec et al. 2012) discuss NIV allows for a great variance in ventilator 
settings from different modes of ventilation. It is considered that high-IPAP has greater effect 
in patients who have CWD have greater response to volume assured modes and the fore 
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4.2.2 Intervention and Comparator 
 
Domiciliary NIV is the use of NIV long-term use overnight in their own home and includes 
studies in which patients were already established on NIV at home. 
High-IPAP will include variations such as high intensity (Windisch et al. 2002) but this is to 
consider patients on a pressure pre-set mode of ventilation. After a review of the literature 
there is no absolute definition of what high pressure is. However, based on previous studies 
the definition for this review will focus on an IPAP ≥ 20cmH2O is to be considered as higher-
pressure ventilation. NIV in pre-set pressure, it is not to include the all mode of NIV such as 
volume assured mode or hybrid modes such as intelligent volume assured pressure IVAP’s. 
And a Low-IPAP will be considered as <19cmH2O on assessment of evidence from 
(Windisch et al. 2002).  
 
Studies were excluded if patients had any other form of NIV such as Via tracheostomy or 
received acute NIV or intubation in acute care setting for treatment of an AECOPD. 
 
4.3 Primary Outcomes  
1. Lung function, FEV1, as patient’s lung function is severely impeded following the disease process 
and is an important marker in determining the treatment course for patients with COPD. 
2.The effect on hypercapnia, derangement of PaCO2 are occur with progression of the disease and 
can be detrimental to the patient relating to respiratory failure.  
3. Compliance as reported by number of hours used and recorded on NIV. 
4.4 Secondary outcomes  
1. HRQOL is severely affected in patients with COPD, there is much conflicting evidence into 
the effect of NIV on QOL and therefore would pose greater in sight to the effect of NIV on QOL. It was 
anticipated due to the variety of outcome measures for QOL in patients with COPD there was 
anticipation that data on this outcome would be heterogenous. 
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2. Exercise capacity in COPD as referred to in Table 2, is reduced because of impaired 
pulmonary function and a reduction in skeletal muscle strength. There is evidence to suggest that the 
use of NIV in patients with COPD improves exercise capacity as there is improved gaseous exchange 
and therefore the ability for skeletal muscle to uptake O2 and utilise. The 6MWT is the common used 
assessment tool for exercise capacity as recommended by GOLD and American Thoracic Society 
(2002). By assessing the effect on NIV on exercise capacity. 
 
3. Reported adverse effects- NIV has a risk of positive pressure ventilation include 
pneumothorax, barotrauma, gastric reflux, haemodynamic instability, higher pressures have been 
reported to pose a risk of leak, asynchronous breaths, pressure ulcer secondary to complications 
associated with the mask (Gay 2009) 
 
4.5  Study Identification 
 
4.5.1 Literature search  
 
Using key words relevant to the outcomes of this review a search strategy was created with 
in conjunction with a librarian at Coventry University. The search was an iterative process 
and was adapted to ensure that the most relevant studies were identified, a full list of 
searches including keywords used, their combination, dates of searches and results can be 
seen in Appendix 4. 
 
The following electronic databases were searched between January 1990 and December 
2017 in February 2018 the Cochrane Library and MEDLINE, CINAHL, AMED via EBSCO 
information services provided by Coventry University. The Cochrane Collaboration discuss 
that in SR of interventions, a variety of databases should be included, and MEDLINE should 
not be the only database searched (Higgins 2011). Table 12 lists the databases included in 
the study each are representative of a variety of medical backgrounds and professional 
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disciplines and covers both published literature and unpublished literature such grey 
literature. A hand search of reference lists of existing SR was completed to identify additional 
studies, Appendix 3 lists SR which were searched. 
 
Once searches were complete they were then stored in RefWorks ProQuest (ProQuest 
Libraries 2017) under database headings. Through this reference management software 
deduplication was completed, however manual removal of duplicated was required to ensure 
that there no article was accounted for twice.
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Study design RCT’s crossover trials 
systematic reviews and meta-
analysis 
Narrative literature reviews, commentaries, 
Quasi experiments and observational studies,  
Publication 
type 
Full articles,  Abstracts alone, letters, conference proceeding, 
ongoing studies and reports. 
Population Adult Stable COPD GOLD III-IV   Studies on lung conditions such as, cystic 
fibrosis, bronchiectasis, OHS, unstable heart 
failure, obstructive sleep apnoea, Tb, chest wall 
deformity  
Intervention NIV High-IPAP compared to low 
IPAP in home setting or home 
use of NIV.  
CPAP, VA NIV, IVAPs 
 
NIV provided in acute setting, NIV via 
tracheostomy, NIV as treatment for AHRF.  
Outcomes  Primary outcomes  
• FEV1  
• FVC 
• PaCO2  
• PaO2  
• pH 
• QOL 
• Compliance with treatment  
 
Secondary outcomes  
• Exercise capacity  
• Hospital admissions 
• Adverse events  
 
QOL reports which are not disease specific to 
NIV. 
Studies which look only at these outcomes. 
 
• SNIPs, MIP, MEP  
• Cardiac outcomes  
• Imaging of lung function 
• Airway resistance,  
• Intubations, QOL, length of stay  
 
FEV1, Forced expiratory Volume 1 second, FVC, forced Vital Capacity, PaCO2, partial pressure 
carbon dioxide, partial pressure of oxygen, pH, potential hydrogens, QOL, Quality of life Nasal 
Inspiratory Pressure, MIP maximum inspiratory pressure, MEP, maximum expiratory pressure, 
OHS Obesity hypoventilation syndrome, CPAP continuous positive airway pressure, VA volume 
assured, IVAP’s intelligent volume assured pressure support, AHRF, acute hypercapnic 
respiratory failure  
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Table 12 Database search and specialism 
 
4.5.2 Screening and Selection  
 
One reviewer screened titles and abstracts for their relevance to the research question 
based on inclusion and exclusion. Once completed and full text articles were identified and 
obtained to include for review copies were obtained and stored on a USB. The study 
selection process and elimination of studies are displayed as the Preferred Reporting for SR 
Items for systematic reviews and Meta-Analysis (PRISMA) flow diagram (Shamseer et al. 
2015). 
 
4.5.3 Data extraction  
 
 was conducted using a form which was devised in Microsoft Word by one reviewer please 
see Appendix 7, the form was developed with the research question in mind. Continuous 
Database search Specialism   
 
EBSCO -Allied and 
Complementary Medicine 
Database (AMED) 
Medical database focuses on specialist allied to 
medicine including physiotherapists, occupational 
therapists 
Grey literature  
Cochrane Library  
Cochrane Central Register of 
Controlled Trials, Cochrane 
database of Systematic Reviews 
(CDSR), Cochrane central 
Register of Controlled Trials 
(CENTRAL), Cochrane 
methodology register (CMR), 
database or Abstracts of Effects 
(DARE), Heath Technology 
Assessment Database (HTA), 
NHS economic evaluation 
database (EED) 
Health care interventions 
 
RCTs and systematic reviews grey literature 
EBSCO- National Library of 
Medicine’s MEDLINE 
Biomedical Literature 
RCTs, systematic reviews, 
EBSCO -Cumulative Index to 
Nursing and Allied Health 
Literature (CINAHL)   
Nursing and allied Health Literature  
Conference proceedings, RCTs and systematic 
reviews  
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data on the available outcomes were collected, the data collection form was not originally 
piloted. Data was collected on the patient characteristics, intervention, and comparator and 
available outcomes. any additional outcomes outside of the scope of this review were noted. 
Studies where assessed for potential sources of heterogeneity as it would make help to 
define the best approach to analyse the data. Mean difference, standard deviation and 
confidence intervals were extracted from each study on the available outcomes. The data 
was then tabulated, and characteristics were summarised from each study to determine 
appropriate way to synthesis data as can be seen in Table 13.  
 
4.5.4 Assessment of Risk of Bias  
 
The articles were assessed against the Cochrane Risk Bias tool for RCT’s in Review 
Manager software 5 (RevMan 5)Error! Reference source not found.. The domains 
included from the tool were random sequence generation, allocation concealment, blinding 
of participant and personnel, incomplete data and selective reporting. Using the Cochrane 
handbook for guidance studies which had 3 or more domains as low risk were stratified as 
low risk study. If studies scored a total of 3 or more high risk with unclear they were classed 
as high-risk studies. The Critical Appraisal Skills Programme (CASP) tool for critical 
appraisal of randomised control trials was used to assess quality of  RCT’s (Critical 
Appraisal Skills Programme 2017). The two methods for assessment of quality of evidence 
were chosen as they are both accessible and provide appropriate prompts to ensure the 
right quality of the study is included in the systematic review. In a systematic review of 
critical appraisal tools completed by Zeng and colleagues (Zeng et al. 2015) they analysed 
the 21 critical appraisal tools CASP had a variety of assessment tools. CASP have a tool for 
RCTs and SR, the tool was developed for educational purposes and does not poses a 
scoring system, the tool considers the methodological quality and robustness of the 
research. The Cochrane risk bias tool for RCT’s is recommended by the Cochrane 
collaboration, the tool provides a clear guide in which, assess the limitations of the studies 
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included in the review and therefore provide a more reliable conclusion in the systematic 
review (Higgins 2011) 
 
4.5.5 Data Synthesis and Analysis  
 
As recommended by the Cochrane Collaboration (Higgins 2011) and the Centre for Reviews 
and Dissemination (2009) a narrative synthesis and quantitative synthesis was undertaken 
to assimilate the results of this review. Study characteristics were tabulated, they were then 
reviewed, and a meta-analysis was completed on the outcomes where two or more studies 
were being reviewed in studies with close to similar methods. First an inverse variance, fixed 
effects meta-analysis was completed to review the standard mean difference, then a 
sensitivity analysis by removing low risk of bias studies and completing an analysis on high 
quality studies only. By completing a sensitivity analysis, it explores the robustness of the 
results, by assessing the degree at which results from studies with poor methodology effects 
the overall results (Centre for Reviews and Dissemination 2009). 
  
A visual assessment of heterogeneity was assessed by reviewing overlap of confidence 
intervals for the effect size of each study. The potential clinical and methodological sources 
of heterogeneity include age of patients, time points of results taken, methods to assess LF, 
number of days on NIV and intervention characteristics, units of measurements may have a 
potential source of heterogeneity and adequate presentation of data. An assessment using 
the chi2 test and p value was used to assess if there was any heterogeneity in the results a 
large p value was deemed as a significant level of heterogeneity. I2 was used to quantify the 
amount of heterogeneity which is present, if I2 > 50% was considered moderate 
heterogeneity (Higgins 2011) a random effects meta-analysis was completed if a sub-
analysis was deemed appropriate. 
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A narrative approach was taken where only one study was identified or if the study if there 
was substantial heterogeneity was detected. The narrative approach was undertaken to 
summarise results between studies. Due to the small number of studies with a small sample 
size an assessment of publication bias using funnel plots was not appropriate (Lau et al. 
2006) 
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4.5.6 Ethics  
 
Ethics approval was sort from Coventry University research ethics committee and was 
deemed low risk of causing harm. The Health Research Authority research framework and 
(Health Research Authority 2018) that research should not be done to the patient, but is 
should be done with the patient for the patient in mind. It is quite a powerful statement and it 
challenges traditional practices where by research was conducted and the only involvement 
of the patient was as being a participant. As research culture has evolved and with ethical 
codes of conduct incorporated into legislation reporting, ethical considerations demonstrate 
a strong and robust approach to research. 
 
4.5.7 Data protection 
In a systematic review although this is not primary research it involves exploring data bases, 
the collection and storage of data and storing data and exploring primary research involving 
human participants. Therefore, measures needed to be taken to ensure that there is 
adequate authorisation to share data. To maintain confidentiality data was stored on a 
password protected computer and USB storage device. In line with the data protection act 
(Legislation.Gov.Uk 2005) it is planned that once the investigation is completed that it would 
be destroyed.  
 
4.5.8 Funding  
 
The systematic review was completed as part of an academic requirement from a Health 
Education England/ National Institute of Health and Research funded Master by research at 
Coventry University. There are no conflicts of interest and there all views stated are that of 
the authors. There were no addition costs to the NIHR for the completion of the project.  
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Figure 7 Flow Diagram depicting article selection 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097 
Some materials have been removed due to 3rd party copyright. The unabridged version can be viewed 
in Lancester Library - Coventry University.
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Table 13 Characteristics of Randomised Control Trials 
Characteristics of RCT’s 
Author, Year, 
 Country 




Number lost to 
follow up with 
reason 
 
Mean Age  Intervention  






Secondary Outcomes Other Outcomes 







Single Centre, Randomised 









1 Refused not 
tolerant of LI 
NPPV 
1 Stopped LI-























of hours of NIV, 





Borg Dyspnoea scale 
(Dreher et al. 2011) 
Germany 
Single Centre  






2 Nights  
4  






















Sleep Quality Body Polysomnography 
Oxygen Desaturation Index 
 
Duiverman et al. 2017 
Netherlands 
Single centre Randomised 






























Cardiac Output, Respiratory Muscle 
strength 
LI-NPPV-Low Intensity Non-Invasive Positive Pressure Ventilation, HI-NPPV- High Intensity Non- Invasive Positive pressure Ventilation, PaCO2- partial pressure Carbon dioxide, PaO2-partial pressure Oxygen, FEV1 -
forced expiratory volume in 1 second, FVC-forced vital capacity, Mbar- millibar, CMH2o- centimetres of water, HRQOL- health related quality of life, SRI SS-Serious respiratory insufficiency questionnaire sub scale, 
IPAP- Inspiratory Positive Airway Pressure 
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 Results and Findings 
5.1 Summary of Results  
During the search 1613 studies were identified after removal of duplicates from the listed 
databases, there were no additional studies identified from hand searching reference lists of 
systematic reviews. The PRISMA flow chart in Figure 7 demonstrated the selection process 
for assessment of included studies in results. After screening titles and abstracts 6 studies 
were identified to review for text analysis, full text article was not available (Chen et al. 2011) 
despite a search by conducted by Coventry University Library therefore was not included 
and was excluded. A further two studies by Duiverman and colleagues (2017) and Schwarz, 
Magnet and Windisch (2017), were excluded due to methodology of literature review. 
Duiverman and colleagues (2017) compared high Intensity positive pressure compared to 
low intensity positive airway pressure in COPD patients however, 10 patients were assessed 
on four variations of HI-NPPV and LI-NPPV for only 15 minutes with spontaneous breath in 
between and was not and RCT design. The settings were randomly generated however, and 
each patient had a varying sequence of generation of pressure settings and was not a RCT. 
Schwarz and colleagues completed a narrative literature review of HI-NPPV compared to LI-
NPPV there was no evidence of a systematic selection process of articles to include in the 
review therefore did not fit in the criteria, a summary of this can be found in Appendix 1, 
Table 16. Three randomised control trials were included in the systematic review and from 
hand searching no additional studies were identified from the systematic reviews that were 
not already located through database searching Table 13 demonstrates the characteristics 
of the randomised control crossover trials.  
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5.2  Study Characteristics  
5.2.1  Study population Participants  
A total of 48 patients with a diagnosis of COPD GOLD stage III and IV were identified, all 
studies had the absence of MND, OSA/OHS, pneumonia, bronchiectasis and post TB 
sequalae.  Participants were recruited with a PaCo2 of >6.4 and had not displayed any signs 
of acute exacerbation of COPD. Participants were all described as having stable COPD 
managed with standard medical therapy or described usual care as inhaled bronchodilators, 
inhaled corticosteroids and LTOT. Studies were poor in reporting demographics however the 
average age was between 63 and 69 as described in the studies.   
 
5.2.2  Intervention and comparator 
All three RCT’s had received domiciliary NIV established prior to recruitment to the study 
recruitment, one RCT included a patient who developed decompensated respiratory failure 
during their intervention and was subsequently withdrwarn from the study and not included in 
the final analysis. Intervention provided varied in length of time to follow up, Duiverman 
(2017) and Dreher (2010) had 6 weeks follow up compared to Dreher (2011) with a follow up 
of 1 night.  
 
Protocol in which NIV was initiated included an overnight admission and NIV pressures were 
recorded in similar protocols and IPAP was increased until participants could tolerate IPAP 
of above 23CMH2O. the lowest IPAP recorded was 14CMH2O (14Mbar).  Once patients 
tolerated settings they were discharged and returned for follow up.  Dreher and colleagues 
(2011) acclimatised patients to high IPAP, patients then received the intervention before 
being switched to low IPAP.   
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5.2.3  Risk Of bias within studies 
To review full quality assessment details and CASP tools on RCTs they are listed in Error! 
Reference source not found. and RCT’s from assessment using the Risk Bas tool. Figure 
8 depicts the variation in quality in the domains of the risk bias tool of the included studies, 
all three studies were scored a high risk on random sequence generation, allocation 
concealment and blinding.   
 
Blinding of participants and personnel risk bias for 2 RCTs was high, as there was no 
blinding reported, one trial reporting blinding of the assessor and scored low on this 
category. For the categories of blinding of outcome assessment two studies scored low and 
one study was unclear risk, outcomes used for the trials were objective measures and 
therefore unlike likely to be affected by bias. Therefore, objective outcomes such as ABG 
and ET are unlikely to be affected by bias. However, for studies that assessed subjective 
measures such as the Borg dyspnoea scale and the SRI scale there could have been 
affected by bias and therefore have an influence on the results.  
For the category of incomplete data two trials scored an unclear risk and trial scored a high 
risk of bias secondary to lack of reporting subjects who had withdrawn from the trial and 
attrition bias due to the number of patients who had withdrawn from the studies. 
All outcomes were reported as the study had discussed and therefore had a low risk of bias. 
Other factors considered in trials were carry over effect, as discussed patients were not 
naïve to NIV particularly HI-NPPV. 
 
57 | P a g e  
      
  














5.3  Primary Outcome   
Results from a meta-analysis on PaCO2, FEV1 were completed, the results are as follows Appendix 2 
lists studies included in meta-analysis.  
5.3.1 Effect of High IPAP compared to low IPAP on hypercapnia  
All 3 studies reviewed the effect of high-IPAP on hypercapnia with three studies, pooled data 
favoured high IPAP compared to low IPAP for reducing PaCO2 with a standard mean 
difference with a reduction of PaCO2 by -0.39Kpa (95% CI [-0.96, 0.19]) no statistically 
significant difference (p=0.19) and results were homogenous (I2=0%, p=0.83) as can be 
seen in Figure 9 and Figure 10.
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Figure 9 Effect of High-IPAP Compared to Low-IPAP on Reduction of paCO2 
 
Units: Kilopascals (Kpa), SD- standard deviation, IV inverse variance, CI confidence Interval  
 
Figure 10 Analysis on High Quality studies only 
 
Units Kilopascals (Kpa), SD- standard deviation, IV inverse variance, CI confidence Interval  
An analysis one high quality study demonstrated that results favoured high-IPAP with a 
reduction in PaCO2 a treatment effect of 0.63Kpa (95% CI - [-1.61, 0.32]) however there is no 
significant difference (p=0.21). 
 
5.3.2 Effect of high IPAP versus low IPAP on FEV1 
Two studies were identified reviewing the effect of IPAP on FEV1 Both studies were with a 
total of 31 participants. Results appear to favour low IPAP. On analysis of the results 
demonstrating that there was no significant difference (P= 0.30) in the effect of high-IPAP 
compared to low IPAP on FEV1 however there was an improvement in FEV1 with a mean 
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difference of 0.39l (95% CI [-0.35l, 1.12l] ). There was evidence of moderate heterogeneity in 
results (I2=53%, p=0.14).  
A random effects meta-analysis was completed to account heterogeneity, as can be seen in 
Figure 12, there was no statistically significant difference (p=0.49) (95% CI 0.38 [-0.69,1.45]) 
results were moderate heterogeneity (I2=0% p=0.14) as can be seen in Figure 11. 
Figure 11: Effect of High IPAP compared to low IPAP on FEV1 Fixed effects 
meta-analysis  
 
Units: litres (l) standard deviation, IV inverse variance, CI confidence Interval 
 
 
Figure 12 Effect of High-IPAP Compared to Low-IPAP on FEV1 Random Effects Meta-
analysis 
 
Units litres, SD- Standard deviation, IV inverse variance, CI confidence Interval  
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5.3.3 Effects of High-IPAP ventilation compared to Low-IPAP on 
exacerbation rates. 
No study investigated the effect of pressure settings on exacerbation, Duiverman and 
colleagues (2017) discuss two patients were readmitted secondary to worsening 
hypercapnia when switched to the low-pressure intervention with a PaCO2 increase to 
10Kpa there are no further discussions on the follow up these patients to determine if this 
was secondary to an exacerbation.  
 
5.3.4  Effect on adherence.  
Two studies were found to investigate the effect on adherence both measure in number of 
hours however Duiverman and colleagues (2017) reviewed the median lengths of time on all 
patients who completed with a standard deviation compared to Dreher (2010) who recorded 
the mean length time completed for each period. Due to the differences in recording of data 
a meta -analysis was not completed. A median length of time on NIV for High-IPAP was 
10.8hours compared to a mean of 7.7 hours spent on nocturnal NIV. 
 
5.4 Secondary outcomes  
 
A meta-analysis could only be completed on HRQOL, the results are as follows. 
5.4.1 Effects on Health-related quality of life 
 
Two studies analysed the effect of high-IPAP on the HRQOL Figure 12 with 6 weeks follow 
ups using the Serious Respiratory Insufficiency questionnaire. The results demonstrated that 
there was no significant difference between different settings and Health related quality of 
life (p=0.77) (95%CI 0.11 [-1.17,0.95]) there was no heterogeneity in results (I2=0%, 
P=0.59).  
 
61 | P a g e  
      
  
Figure 12: Effect of high pressure compared to low pressure on the HRQOL 
 
Standard deviation, IV inverse variance, CI confidence Interval  
 
5.4.2 Effects of high-IPAP compared to low-IPAP on exercise 
tolerance 
Table 14 Error! Reference source not found. illustrates that one RCT (Dreher 2010) 
investigated the effect on ET and recorded the six-minute walking distance, there was an 
increase in ET in both interventions with a between group difference of 14m, however it was 
not statistically significant (95%CI [-42m, 70m] p=0.58), the results were homogenous with 
(I2=0%). 
 
5.4.3 Reported adverse events  
 
All three studies did not categorise serious adverse events, but, are discussed in terms of 
reasons for withdrawal, Error! Reference source not found. possible risks. Duieverman and 
colleagues (2017) discuss the increase in PaCO2 when switching from Hi- NPPV to Li- NPPV 
a rise of 10kpa is recorded in addition a participant who developed decompensated heart 
failure during the intervention. Dreher and colleagues (2011) report participants withdrawing 
to due to fear of asphyxiation. 
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Table 14 secondary Outcomes Exercise Capacity 
Secondary Outcome Exercise Capacity 
 













95% Confidence Interval 
between group difference   
After 6 weeks (M) 
Comments 















Mbar- Millibar, 6MWT-6 Minute Walk test, LI-NPPV-Low Intensity Positive Pressure Ventilation, Kpa- Kilopascal, HI-NPPV-High Intensity Non-
Invasive Positive Pressure Ventilation.  
 
 
Table 15 Secondary Outcome reported Adverse events 
 
 Reported Adverse Events 
Author, Year Serious Adverse 
events recorded  
Details  
(Dreher et al. 2010) No  2 patients withdrew due to rise in dyspnoea secondary to switch from 
Li-NPPV to Hi-NPPV 
1 withdrew secondary to intolerance of LI-NPPV settings 
(Dreher et al. 2011) No 4 patients withdrew due to refusal to sleep under lower pressures 
2 following fear of asphyxiation to sleep under Li NPPV no report of the 
reasons behind withdraw of 2 participants 
(Duiverman et al. 2017) Yes 1 patient decompensated heart failure after 5 weeks in Hi-NIV arm, 
2 patients did not tolerate the change from Hi-NPPV to lI-NPPV 
Rise in PaCO2 to 10Kpa  
LI-NPPV-Low Intensity Positive Pressure Ventilation, Kpa- Kilopascal, HI-NPPV-High Intensity Non-Invasive Positive Pressure Ventilation, PaCO2,  
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6.1 Summary findings  
 
 
The primary objective of the systematic review was to analyse and synthesise available 
evidence on the effects of High-IPAP compared to Low-IPAP on specific patient outcomes 
who were receiving domiciliary NIV with a diagnosis of COPD to ascertain the most effective 
way to ventilate patients with home NIV. The review identified 3 RCTs, a meta-analysis was 
completed on outcomes where a minimum of two studies which investigated the same 
outcome. Forrest plots for outcomes (hypercapnia, lung function and quality of life) were 
completed and a narrative synthesis completed where there was only one study available. 
The results for the systematic review demonstrate that there was no significant difference 
between the effect of high-IPAP compared to Low-IPAP on hypercapnia, lung function and 
HROQL. There is paucity in evidence analysing the effect on exacerbation rate, exercise 
capacity and adverse effects of NIV. However, from reviewing the literature this is the first 
time a systematic review has directly addressed the question to establish the effect of high-
IPAP ventilation compared to low pressure ventilation in COPD patients receiving domiciliary 
NIV. This review has highlighted that there is a gap in the evidence and therefore knowledge 
base in the effect of pressure settings on patients physiological and a clinical outcome 
 
6.2 Primary Outcomes  
 
All three studies were randomised open labelled cross over designs. As a result, this 
reduces the likelihood of a carryover effect (Cochrane 2011) which may have been an issue 
as there may have been carryover for the primary outcomes (PaCO2 and FEV1,). This 
method was discussed with a statistician at Coventry University to ensure the appropriate 
method was conducted and to ensure that each patient was not counted twice (Elbourne et 
al 2002) 
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6.2.1 Arterial blood gases  
 
One of the possible advantages of high-pressure ventilation in patients with COPD included 
the reduction of PaCO2. On analysis on high quality study there was a reduction in PaCO2 
which favour high-IPAP in (Vogelmeier et al. 2017) all three RCT’s. Data suggests there is 
no significant difference (p=0.19) between the High-IPAP compared to low-IPAP on COPD 
patients receiving domiciliary NIV with a reduction of Paco2 a mean difference of -0.39Kpa 
(95% CI [-0.96, 0.19]). On sensitivity analysis, data suggest an improvement in PcO2 the NIV 
is more favourable in patients who receive High-IPAP compared to low-IPAP however there 
is no significant difference. It is not yet fully understood the long-term physiological effects of 
the effect of NIV on hypercapnia.  In all three-studies patient population were not naive to 
high-IPAP NIV and it may be possible that there was carry over effect upon entering the trial. 
It is not yet known how long the effects however with an increase in alveolar ventilation, 
there is greater gaseous exchange and a greater chance in reduction of PaCO2 (Borba 
Monteiro et al. 2012, Petersson and Glenny 2014).  Although there is no statistically 
significant difference on sensitivity analysis due to the unknown long-term effects on 
dynamic hyperinflation. 
 
NIV is hypothesised to reduce work of breathing (WOB) and airway resistance, this can 
improve respiratory muscle activity. The scope of this study did not seek to analyse the 
effect of High-IPAP compared to low-IPAP on the respiratory muscle function in patients. 
However, a recent study into the effect of HI-NPPV on participants respiratory muscle 
function, patients were exposed to four varying pressure sequences for 15minutes at a time 
and underwent electromyography to assess respiratory muscle activity (Duiverman et al. 
2017) established that there was a decrease in respiratory muscle activity in patients who 
had a HI-NPPV compared to patients who had LI-NPPV. It demonstrated that NIV leads to 
respiratory muscle unloading and allows for greater control of the ventilation system 
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therefore an improvement in ventilation. It must be said however this study had a short follow 
up time on NIV and cannot be taken as long-term effects of ventilation on the respiratory 
muscles. Further studies in this area are needed to substantiate this theory. 
 
There were limitations in data reporting on all RCT’s, studies had incomplete reporting of 
baseline characteristics therefore this may lead to unreliable between group differences. 
There was Dreher and colleagues (2010) reported on the effect on PaO2 in which there was 
minimal effect on patients, however all patients had received supplementary oxygen. Due to 
the disease progression patients have a reduction in PaO2, under the BTS guidelines 
(Hardinge, Suntharalingam and Wilkinson 2015) oxygen LTOT can be prescribed to patients 
who are hypoxemic however it should be used appropriately as, COPD positions patients at 
a high risk of acidotic respiratory failure and it is important to control the flow of oxygen in 
patients receiving LTOT with a diagnosis of COPD and hypercapnic respiratory failure. 
Supplementary O2 can also be of benefit for patients with HRF by stabilising PaCO2 (Stodart 
2017) as it increases intrinsic PEEP a reduction in hospital admissions with NIV in 
combination with NIV compared to LTOT alone a result of stabilising PaO2 (Murphy et al. 
2017) . Therefore, this is one variable that would require to be assessed in detail to ascertain 
that any change in PaCO2 was because of the higher pressures or higher pressure in 
combination with supplementary O2.  
 
6.2.2 Lung function 
 
Data from the meta-analysis suggest that there is no significant difference between the effect 
of high-IPAP compared to low-IPAP on patients with COPD and their FEV1 (p= 0.30) (95% 
CI 0.39l [-0.35l, 1.12l]). there was moderate heterogeneity in the results with I2 53% p 0.14 
with Dreher 2010 favouring low-IPAP and Duiverman (2017) favouring high-IPAP. 
Heterogeneity in the results could not be explained by a sensitivity analysis as they both 
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scored the same on quality of studies. A random effects meta-analysis was completed to 
assess for the differences in treatment effect. there was no statistically significant difference 
with a p value 0.39. The studies have wide confidence intervals due to the small sample of 
patients studied and therefore the results are less precise. Another explanation for the 
heterogeneity was one patient in Duiverman (2017) was admitted with severe hypercapnia 
prior to cross over and therefore there is a possibility that there was a reduction in FEV1 
preceding admission. LF has a significant decline as the disease progresses and there is a 
marked reduction in FEV1 and FVC. 2 RCT’s investigated the effect of pressures on LF and 
each demonstrated that there was an increase in FEV1 both RCTs, although there was an 
increase which was favourable towards higher pressure settings this increase was not a 
statistically significant differences between high-IPAP and Low-IPAP FEV1 although an 
objective measure is not the only marker of lung volumes and there is no minimally important 
clinical difference to measure improvement and it suggested that a difference of between 
100-140ml may be considered as an improvement Glabb and colleagues (2010). The 
measurements used to assess FEV1 included the body plethysmography, this is an objective 
measure which is unlikely to be affected by the patient bias. It is said to be more accurate 
the assessment of patient’s LF compared to spirometry (Wanger et al. 2005) and is a 
measure which is unlikely to be subjected to performance bias. As a widely used outcome 
measure of airflow limitation to establish treatment outcomes RCTs patients were 
categorised GOLD category COPD IV. There is a greater understanding of the pathogenesis 
of COPD in reviewing FEV1 and FVC as an outcome, it will provide further information as to 
if NIV effect the progression of the disease, and longitudinal studies are needed to assess 
this phenomenon.  
  
6.2.3 Adherence  
 
Two studies (Dreher 2010, Duiverman 2017) assessed adherence as an outcome however a 
meta-analysis could not be completed on secondary to the method of measurement and 
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recording of data. As a result, a meta-analysis could not be completed, to obtain the results 
required to complete a meta-analysis contact with the authors would have been beneficial 
however due to the time constraints of the project this was not feasible. It is reported that 
both studies participants were using on average more than 4 hours a day.  
 
For NIV to have a greater effect on diurnal pattern there should be use of more than 4≥ 
hours or more (Masa and Corral-Penafiel 2014) on average patients were using NIV more 
than 9 hours. It is thought that higher pressures in COPD patients improves tolerability 
because of respiratory muscle unloading and by overcoming airway resistance (Windisch 
2011). Murphy (2012) demonstrated in a small cross over trial that higher pressures in NIV 
are not only justified but also tolerable and patients were adherence to higher pressure 
ventilation >28cmh20.  
 
It would be beneficial for further studies to review the impact of pressure on adherence to 
treatment. Technology such as the use of remote monitoring of patients in NIV may be 
implemented in further trials, providing information, on number of hours on NIV, tolerance of 
pressures and asynchronous events. In the future telemonitoring may be away of assessing 
and predicting if patients are at risk of an exacerbation by recording patient ventilator 
interactions, trends in a pattern of reduced tidal volumes, reduction in the number of hours 
on NIV and number of asynchronous activities. It may offer a solution into reducing hospital 
admissions in clinical practice and improve quality in care and practice (Arnal, Texereau and 
Garnero 2017). 
6.3 Secondary Outcomes 
 
6.3.1 Health related quality of life  
Quality of life is severely diminished in COPD patient’s, data from this systematic review 
demonstrate that there was no statistically significant difference in pressure and HRQOL 
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(p=0.77) with improvement in HRQOL favouring high-IPAP (95%CI 0.11 [-1.17,0.95]) results 
were homogenous (I2 =0, p=0.59%). This is in support previous reviews which suggest NIV 
in combination with standardised care is not superior to standard care alone in terms of 
improving quality of life this supports findings. It is also supported by a previous study by 
Tissot and colleagues (2015) discuss long-term NIV in the elderly has little effect on patients 
HRQOL in a multicentre cohort study investigating the effect of NIV in the elderly. Upon 
entering the study their characteristics were recorded and were followed up 4 months after 
initiation and were then followed up routinely to assess their ventilator adherence which was 
assessed by mean ventilator usage. The cohort were split into two age groups >75 and ≤ 75. 
The following outcomes were reviewed, sleep quality, cognitive assessments, Medical 
outcome Survey Short form Health Survey (SF-36), with physical component summary and 
mental component summary scales and subscale. Their results demonstrate that there was 
some improvement at 6 months however compared to the elderly seem to have a less 
benefits in their QOL, however the study investigates QOL on elderly patients who have 
CHRF, with the SF-26, although valid in the use with patient with long-term conditions to 
analyse to determine the effect of treatment, it is not disease specific. The Severe 
Respiratory Insufficiency Questionnaire was valid for COPD a patient with severe chronic 
respiratory failure questionnaire is designed for use in patients with CHRF and particularly 
with the use of NIV (Windisch et al. 2008).  
 
As discussed by Crimi and colleagues (2016) a perceived benefit of domiciliary NIV is to 
improvement in QOL however this systematic review has demonstrated is no significant 
difference between those who are ventilated with High-IPAP compared to patients who were 
ventilated with Low-IPAP. As QOL is an outcome measure which is used to determine 
clinical effectiveness and guide long term treatment for patients receiving domiciliary NIV, 
future trials should investigate the effect further. 
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6.3.2 Exercise tolerance  
ET was recorded in one trial only (Dreher 2010) as a result no meta-analysis was completed. 
Result were tabulated Table 20 and demonstrated that there was no significant difference 
exercise tolerance (95% CI 14 [-42-to 70] p=0.58), however it is difficult to define if any 
improvement in exercise capacity was attributed to a high-IPAP. During the 6-minute walk 
test an improvement of 54-80m needs to be seen to determine an improvement in exercise 
tolerance (Glaab, Vogelmeier and Buhl 2010). It is not discussed if patients were receiving 
pulmonary rehab or engaging in physical activity. Both GOLD and NICE discuss the benefits 
of pulmonary rehab and prescribed physical activity to increase patients HRQOL, improve 
dyspnoea, improve self-management and reduce exacerbations. Unfortunately, there are no 
details on the non-pharmacy management of these patients and this is therefore speculation 
that any increase in ET may be attributed due to an improvement in skeletal muscle strength 
due to an increase in physical activity. In an RCT investigating the effect of NIV and ET (van 
't Hul et al. 2006) group were given IPAP of 10cmH20 and the control group were exposed to 
IPAP of 5cmH2o. Following an 8-week supervised outpatient exercise programme patient 
were assessed at baseline for their HRQOL using the SGRQ, shuttle walk test and a 
constant load cycle endurance performance test, they were then tested after the 8 weeks of 
intervention and results demonstrated a statistically significant improvement in their exercise 
endurance, there was improved walking distance there was however no difference in SGRQ 
score. 
 
In future studies it could be suggested that this is investigated further, however after 
pulmonary rehab patients have an increase in ET as there would be a reduction in dynamic 
dead space and therefore adequate ventilation and perfusion allowing for a more efficient 
gaseous exchange (Salturk et al. 2015). If there is more efficient gaseous exchange there is 
an increase in the uptake of oxygen by the skeletal muscle.  Recent studies into the effect of 
as an adjust in pulmonary rehab suggest there is a place for its use in improving dyspnoea 
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and allowing patients to exercise longer (Puhan et al. 2011) In a systematic literature review 
by Corner and Garrod (2010) discussed the benefits of NIV in addition to pulmonary rehab, 
in which they concluded, NIV may increase exercise intensity in moderate to severe patients 
however the validity and reliability of evidence is questionable. 
 
On the available study there is evidence suggesting that there is no significant improvement 
in exercise tolerance and high-IPAP. Further studies are required to enhance understanding 
of this this outcome.  
 
6.3.3 Exacerbation   
 
No study recorded exacerbation or readmission rates. It is reported in Duiverman (2017) that 
two patients were admitted secondary to a rise in PCO2 of >10Kpa when patients received 
NIV in the low-IPAP treatment arm, however there are no further details provided to 
ascertain if this was secondary to exacerbation of COPD. Murphy and colleagues (2018) 
have demonstrated a improvement in time to readmission for patients receiving domiciliary 
NIV, LTOT and standard medical therapy compared to medical therapy alone. Murphy and 
colleagues (2018) predominantly used pressures median >28CMH20 during this trial and 
this relatively high IPAP may be attribute to the improvement in time to readmission. Further 
studies are required to investigate this phenomenon as there is no detailed data available to 
analyse. As a result, no conclusion could be drawn for this outcome as there no studies were 
identified.   
 
6.3.4 Adverse Events  
 
There was limited discussion on adverse events out of the three randomised open labelled 
cross over trials. Table 14 displays serious adverse events recorded resulting in hospital 
admissions for Duiverman (2017) two patients were admitted secondary to an increase in 
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their PaCO2 and one patient was admitted following decompensated heart failure. They 
could be considered as an adverse event by WHO definition as an untoward medical 
occurrence during a clinical investigation (World Health Organization Quality Assurance and 
Safety of Medicines Team 2002). Reporting of adverse events in clinical trials are poor, 
however it is vital to report any adverse events are particularly for practitioners to consider 
treatment is beneficial and harms (Schulz, Altman and Moher 2010). Due to the poor 
reporting and follow up it is not possible to ascertain whether the increase in PaCO2 was a 
result of poor follow up or due to a reduction in pressure or a possible sign of a deterioration 
in disease status or possible AECOPD. One explanation for the increase in PaCO2 is 
possibly due to not achieving the desired MV, resulting in asynchronous breath which 
increase the load on respiratory muscles in pressure <19CMH2O (D. R. Hess 2011) 
therefore inadequate gaseous exchange leading to an increase in PaCO2 both in 
spontaneous breathing and NIV overnight (Tuggey and Elliott 2006). 
 
It is also noted that Dreher and colleagues (2011) report that two patients were lost at cross 
over they did not want to sleep under low-IPAP as they reported the feeling of asphyxia. The 
feeling of asphyxia is normally associated with placement of an interface such as a oronasal 
face mask (Gay 2009) Figure 6. It is an interesting finding and patients withdrew from the 
trial following this fear. It is noted that there were no serious adverse events however it also 
not discussed what procedures were in place to safeguard patients against serious harm.  
 
There is not enough detailed data evident to assess adverse events, there is paucity in the 
studies as to what is classed as an adverse event, whether there was a measurement for 
adverse events and how an adverse event was identified and document. Further studies 
should be conducted in this area to assess the effect of NIV pressures and adverse events.   
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6.3.5 Generalisability  
 
In relation to the scope of the review question, it asked a specific question which was aimed 
to assess individuals who were receiving NIV as an additional form of management for 
COPD. There were limitations in the inclusion and exclusion criteria as discussed, studies 
identified as a result were limited to English language as a result participant were from 
western European countries who followed GOLD (2017) standard of care guidelines. The 
average of age of participants ranged from 63 and 67 with an FEV1, <0.7 this is a typical 
presentation of patients with end stage COPD.  
 
NIV is recommended in NICE guidelines (2010) and GOLD (2017). The results from this 
review are applicable to patients from this demographic for patients with end stage COPD 
GOLD stage 4 classification where domiciliary NIV is accessible. The results are specific to 
patients with COPD, other long-term respiratory condition (CWD, OHS, OSA, and NMD) 
where patients may suffer from chronic hypercapnic respiratory failure should use these 
results with caution as respiratory pathologies may require different ventilatory modes, 
settings (Rabec 2011) and further investigations should be carried out to assess the 
applicability of the results to other respiratory conditions.    
 
6.3.6 Sensitivity analysis  
 
The sensitivity analysis on analysing the effect on hypercapnia was completed to assess the 
effect of the robustness of the studies on the results (Cochrane 2011). On sensitivity 
analysis there was no significant difference between the effect of High-IPAP compared to 
Low-IPAP. This demonstrates that there was no influence on the quality of the trial on the 
results. However, the confidence intervals were wide, and this is largely due to the relatively 
small quantity of patients that were sampled, therefore although there is a more favourable 
outcome towards high-IPAP there it cannot be said with certainty, despite pooling of data 
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together, as demonstrated in the meta-analysis. Further studies are required with a large 
sample of patients.   
   
6.3.7 Limitations of the study  
 
As with all studies there are limitations, the search strategy was conducted in conjunction 
with an experienced librarian. To ensure that there was an effective database search was 
completed the search was conducted in collaboration with the subject librarian as to the best 
way to construct search syntaxes to ensure relevant studies were accounted for and advice 
sought on the bibliographic databases to utilise. In the involvement of systematic reviews, 
they are becoming more valuable and involved in health care research. In a scoping review 
Spencer and Eldredge (2018)to assess the role of librarians in a systematic review they 
concluded that there are up to 18 roles where the librarian can perform in a systematic 
review and in health research, they include planning the search, citation management, 
reporting and documenting in adherence to PRISMA format and de-duplication of records. 
Two roles identified in this review for which could be used in the future is for librarians in 
developing the protocol which was not previously considered and using technology and 
analytical tools for predicting the amount to references for a systematic review. The search 
was based on key words designed to detect studies relevant to the systematic review 
question. MeSH were not used and therefore there may have been articles not identified 
form search strategy which was completed. This is a limitation in the search strategy and as 
a result this may not a fully exhaustive search key words were used and if the study was to 
be completed again MeSH Headings would be ideally placed to ensure all relevant articles 
are identified. 
 
Electronic databases were searched for English language studies in the following electronic 
databases available through the Coventry University EBSCO information services and 
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Cochrane which were accessible. Articles and abstracts which were unavailable were 
acquired through the Coventry University library. The Cochrane Library, MEDLINE and 
CINHAL and AMED were bibliographic databases searched there are many other databases 
which could be searched and Lam and McDarmid (2016)discuss that the number of 
databases searched in systematic review and meta-analysis has increased. However time 
constraints were a limiting factor in this case, however it thought that MEDLINE, the 
Cochrane library of systematic review which includes CENTRAL and CINHAL are sufficient 
enough to identify published and unpublished literature (Higgins 2011). 
 
As the construction of the search was limited to English language only this may have been a 
limiting factor as studies which were written in another language were included in the review. 
This is often a common challenge in SR, systematic review teams conduct the review and 
with grants they may provide funding for an addition of a translator and therefore would be 
able to include studies in different languages, introducing language bias. In limiting 
languages there was a restriction to more western culture and as noticed the studies 
identified were European, therefore it would be likely that there may be minimal variation in 
management and diagnosis of patients with a diagnosis of COPD however it is beyond the 
scope of this review to identify the individual management practices of COPD patients in 
each country. But all trials refer to use of GOLD diagnosis and management of COPD 
guideline and therefore the approaches may have minimal or no variation therefore making 
conclusions generalizable to practice in the UK which, is important when making decisions in 
health care. 
 
In addition to searching electronic databases hand searching was completed of identified 
systematic reviews to identify any additional trials not identified during the electronic 
database search. One other limitation of the review was that screening, selection data 
extraction, critical appraisal and evidence synthesis was conducted by a single reviewer, and 
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therefore it is subject to the scope of the authors knowledge and could be considered a 
source of bias. However, a systematic approach was taken in the approach was taken to 
answer the research question.   
 
The initial time plan had changed and amendments were made to ethics in order to allow for 
a change of databases to be included in the search of the Cochrane library, initially a search 
of academic search complete was considered however it would have identified literature 
such as university thesis and conference posters and some clinical academia literature, but, 
would not have been adequate for the question posed in the systematic review, it was a 
learning curve and highlighted the importance of ensuring  the right databases are searched 
for the question asked. 
 
The data collection form was modelled based on literature and with consideration of the 
expected outcomes, however the form was not preliminary tested to establish the adequacy 
of function, in future studies it is recommended that data collection forms are tested on a few 
studies to identify that they are adequate in obtaining the data required (Evelina Tacconelli 
2010). One limitation in data collection was simply that there was data which was not 
recorded, in some cases there was no baseline characteristics or reported in the trials and 
therefore could not be recorded in the form. What was also not considered in data collection 
was the recording of nocturnal and daytime PaCO2 it was not anticipated that both 
measurements were taken and therefore was not accounted for in the data collection form. It 
is not believed that this would affect the results as data which is not reported on was a result 
of the studies not investigating outcomes.  
 
Other methods of assessing the quality of evidence include the Grading of Recommendation 
Assessment and Development and Evaluation (GRADE) (Guyatt et al. 2008)which, would be 
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appropriate to use in when making recommendations for use in health. Guyatt and Gordan 
(2008) discuss the advantage of the GRADE system for making recommendations is there is 
a transition from quality of evidence to strength of recommendations and although both the 
Cochrane Risk Bias tool and the GRADE system are both used in SR and health technology 
assessments, GRADE provides a clear interpretation of what is a strong recommendation 
compared to a weak recommendation. If this systematic review was to be conducted again 
GRADE would be recommended as a method to make recommendations. 
 
The CASP tool was used to appraise the evidence, as discussed it is both easy to use and 
accessible (Zeng et al. 2015). Although originally designed for use for educational purposes 
it is used in systematic reviews (Katrak et al. 2004). It is often discussed that only 50% of 
studies are published (Howes 2017) and studies are likely  to be published if they have a 
statistically significant result. Due to the relatively small number of trials identified publication 
bias was not formally assessed with funnel plots. It is just as important to highlight areas of 
research which may not have had a favourable outcome  (Lineberry et al. 2016).  
 
6.4 Future Works 
 
One of the key messages that was highlighted during this process is, further research is 
required in this area to gain greater understanding. Research which favours positive results 
are most likely to be published however there is much to be gained from research where 
there is no statistical significance and the future recommendation is to set about a new area 
for research. The length of follow up in each study was short and with 6 weeks follow up and 
in one study patients were followed up the following day, there not all outcomes necessary 
were reported and the protocol for NIV however it was dependent on the question asked, 
there was minimal or no blinding in the trials discussed. It was beyond the scope of this 
review to assess the effects of volume assured mode compared to pressure pre-set, and this 
is an area that would be with exploring in the future. A future RCT should be focused on the 
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long-term effects of High-IPAP compared to COPD patients with CHRF, to explore both the 
clinical effects and the physiological effects of long-term NIV.  
 
A longitudinal multi centre RCT should be designed analysing the effect of High-IPAP, 
however it may not be practical to assess as a cross-over trial to lower pressures but, in fact 
a comparator may be assessing the effect of aiming for desired VT or using VA settings. 
Outcomes to consider are LF, dyspnoea, HRQOL, ABG, hospital admission, ET and 
adherence. The length of time required for follow up would be over a year to 24 months with 
intervals of 3 months, 6 months, 12 months and 24 months. This will allow for data to be 
collected on time to readmission or death and create a greater understanding on the 
longitudinal effects of mortality and morbidly. It may then be possible to perform a cost 
analysis to completed based on collected data. Another factor would be to apply a mixed 
methods approach to establish the lived experiences of COPD patients receiving domiciliary 
NIV, this will provide a holistic view of the management of patients. The design of the trial 
should collaborative approach with patients and public.   
 
It was beyond the scope of this systematic review to analyse the physiological effect of NIV 
on the heart, however located one study reviewing patients with heart failure was identified it 
was an interesting find there appeared to be no detrimental effect of the high pressure NIV 
on the heart in patients with heart failure in patients with COPD The RCT demonstrated that 
it is feasible to investigate this phenomenon and future trials should also be encouraged to 
investigate this effect in long-term studies, especially when previously theories suggest that 
an increase in positive pressure leads to haemodynamic changes.
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 Conclusion 
This is the first systematic review completed which has a sole aim to assess the effect of 
pressure on patients with a diagnosis of COPD with CHFRF receiving Domiciliary NIV. The 
aim would be to create recommendations as to what settings would be best when 
prescribing NIV to patients with COPD in doing so making an impact to patient’s long-term 
management. To answer this question following a design of a protocol and a systematic 
search of the literature, a total of 3 randomised control crossover trials were identified. 
 
Following quality assessment and critical appraisal of studies a meta-analysis was 
performed on outcomes where two or more studies identified were performed on the 
(hypercapnia, FEV1 and HRQOL). A narrative synthesis was completed on outcomes where 
only one study completed and assessment. From the outcomes there was no statistical 
difference in the effect of High-IPAP compared to Low-IPAP on patients PaCO2, FEV1, and 
HRQOL although results favoured high-IPAP. There was not enough data provided to 
conduct a meta-analysis on adherence a primary outcome and further studies are required 
to assess this further to understand what drives patient’s compliance with NIV.  
 
There was no data on outcomes for exacerbation rate and poor reporting on adverse effects 
of different pressures. The possible risks identified include a rise in hypercapnia fear of 
asphyxiation when switching to low-IPAP, however there is not enough information provided. 
When prescribing NIV there should be careful consideration as to which pressures are 
tolerable and just when prescribing NIV for domiciliary use. The review has identified that 
further research is needed in this area to ascertain if there is a more efficient and effective 
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Appendices 
 












Reason for exclusion 
 
Comment 
(Schwarz et al. 
2017) 
Why High-Intensity NPPV is Favourable to Low-Intensity NPPV: 
Clinical and Physiological Reasons 
Excluded on 
methodology 
Narrative Literature review 
(Chen et al. 
2011) 
Long-term non-invasive positive pressure ventilation in severe 
stable chronic obstructive pulmonary disease: a meta-analysis 
Unable to Locate Full 
Text article 
Unable to assess from abstract alone, 
full text article not available 
(Duiverman et 
al. 2017) 
Respiratory muscle activity and patient-ventilator asynchrony 
during different settings of non- invasive ventilation in stable 
hypercapnic COPD: does high inspiratory pressure lead to 
respiratory muscle unloading? 
Excluded on 
methodology 
Case Controlled Study design, patients 
were assessed in 15-minute intervals, 
exposed to 4 variations of settings 
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Appendix 2 Studies included in Meta-Analysis 
 
 
Table 17 Table of studies in Meta-Analysis 
 
 
Author, Year Title Method Reason for inclusion 
(Dreher et al. 
2010) 
High-intensity versus low-intensity non-invasive ventilation in 
patients with stable hypercapnic COPD: a randomised 
crossover trial 
Randomised Control 
Cross Over Trial 
Met inclusion criteria on study design, patient 
population, intervention, outcome, 
comparator 
(Dreher et al. 
2011) 
Non-Invasive ventilation in COPD: impact of inspiratory 
pressure levels on sleep quality 
Randomised Control 
Cross Over Trial 
Met inclusion criteria on study design, patient 




Impact of high-intensity non-invasive ventilation on cardiac 
function in stable hypercapnic COPD: a randomised cross-
over trial 
Randomised Control 
Cross Over Trial 
Met inclusion criteria on study design, patient 
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Appendix 3 Identified Systematic Reviews  
 
 









Home mechanical ventilator treatment for chronic obstructive pulmonary 
disease patients with chronic hypercapnia 
Systematic Review Met inclusion criteria on study design, 




The Cost-effectiveness of Domiciliary Non-Invasive Ventilation in 
Patients with end stage chronic Obstructive pulmonary disease: a 
systematic review and economic evaluation 
Systematic Review 
and Meta-Analysis 
Met inclusion criteria on study design, 




The effect of domiciliary non-invasive ventilation 
on clinical outcomes in stable and recently 
hospitalized patients with COPD: a systematic 
review and meta-analysis 
Systematic Review 
and Meta-Analysis 
Met inclusion criteria on study design, 
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Appendix 4 Search Strategy  
 
Database CINAHL (EBSCO)  
search strategies run on the 22/02/2018 
ID Date of Search 
22/02/2018  
Results 
S1 TX “Non-Invasive Ventilation” or “NIV” or NPPV or “Non-Invasive 
Positive Pressure Ventilation” Or “NPPV” or “Bi-PAP” 
7314 
 
S2 S1 and TX “domiciliary NIV” or “Home NIV” 
or “Nocturnal NIV” “Long Term Ventilation”  
3248 
 
S3 S1 AND S2 AND TX “Pulmonary Disease, 
Chronic Obstructive” or “COPD” or “Chronic 
Obstructive Pulmonary Disease” or “Chronic 
Obstructive Pulmonary Disorder”   
1457 
 





Database AMED (EBSCO) 
Search strategies run 20/92/2018 
ID Date of Search Results  
S1 TX “Non-Invasive Ventilation” or “NIV” or NPPV or “Non-Invasive Positive 
Pressure Ventilation” Or “NPPV” or “Bi-PAP” 
88 
 




S3 S1 AND S2 AND TX “Pulmonary Disease, Chronic Obstructive” or “COPD” 
or “Chronic Obstructive Pulmonary Disease” or “Chronic Obstructive 
Pulmonary Disorder”   
2 
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Cochrane library  
  
Search Strategy Run 21/2/2018 
Id Date of Search 21/2/2018 Results  
#1 “Non-Invasive Ventilation” or “NIV” or NPPV or “Non-Invasive Positive 




#2 #1 and Domiciliary NIV or Home NIV or Long-Term Ventilation or 
Nocturnal Ventilation (word variation have been Searched) 
391 
 
#3 #1 AND #2 AND Pulmonary Disease, Chronic Obstructive or COPD or 
Chronic Obstructive Pulmonary Disease or Chronic Obstructive 
Pulmonary Disorder (Word variations have been searched) 
180 
 





MEDLINE (EBSCCO)  
Search Strategies run 20/02/2018 
Id Date of Search Results 
S1 TX “Non-Invasive Ventilation” or “NIV” or NPPV or “Non-
Invasive Positive Pressure Ventilation” Or “NPPV” or “Bi-PAP” 
6615 
 
S2 S1 and TX “domiciliary NIV” or “Home NIV” or “Nocturnal NIV” 
“Long Term Ventilation”  
715 
 
S3 S1 AND S2 AND TX “Pulmonary Disease, Chronic Obstructive” 
or “COPD” or “Chronic Obstructive Pulmonary Disease” or 
“Chronic Obstructive Pulmonary Disorder”   
279 
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Appendix 5 Critical Appraisal frame work for Randomised Control Trials  
 
Table 19 Critical appraisal (Dreher et al. 2011) 
 
CASP Criteria for Randomised 






Did the trial address a clearly 
focused issue? 
Yes  Patients hypercapnic respiratory failure, albescence of lung pathology neuromuscular, chest wall deformity, Overlapping 
OHS, bronchiectasis, bronchial Carcinoma or post Tb Sequalae, pCO2> 50mmhg. Patients not included if they were 
unstable AHRF and with as defined as possessing 2 signs, purulent sputum, C-reactive protein >5mg/dl changes in 
chest x-ray, received NIV in the last 3 months or any form of ventilation 
 




Outcomes- lung function, ABG, polysomnography, overnight oximetry to measure O2 desaturations index (ODI) ≥4% 
and number of desaturations per night <90% the largest decrease was recorded, ECG electrooculograms, digastric 
electromyogram, finger probe Sao2, EEG polygraph, total sleep time (TST), sleep efficiency measured by TST divided 
by time spent in bed, arousals were defined as the appearance of EEG of an α wave 3-15 seconds in duration.  Sleep 
measured by 30 second epochs. 
 
Physiological outcomes were reported on. 
Was the assignment of patients 
to treatments randomised? 
Yes Patients were randomized as reported however no detail on allocation concealment, randomization sequence 
generation. Therefore, risk of bias due to inadequate randomization reporting 
Were all of the patients who 
entered the trial properly 
accounted for at its conclusion? 
Yes   All patients who completed the trial were accounted for, at risk of subject attrition bias due to withdrawal of patients in 
the LI-NPPV to Hi NPPV sequence.  
 
Four patients withdrew >20% of patient population no power calculation was completed. Reasons for withdrawal 
accounted for in flow diagram unlikely to affect results due to power calculation to determine how many participants 
would be required.  
 
Patients were analyzed in both the groups they were in and between group differences were reported. 
2 refused to sleep under LI-NPPV due to fear of asphyxia there is no report of why the remaining 2 dropped out 
therefore there is inadequate follow up.  
 
No details however on follow up of these patients to safeguard from harm.  
 
Due to open labeled study design patients were aware of which treatment sequence they would be on may have 
affected the decision of the patient however due to lack of information on follow up this is purely speculation. 
Continued 1 of 3  
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Were patients, health workers 
and study personnel ‘blind’ to 
treatment? 
Yes  Investigator completing assessment of outcome measures for sleep assessment was blinded to ventilator setting and 
subjective evaluation, however it is unlikely to have influence by researcher or participant due to the outcome measures 
used. Therefore, reduces the risk of researcher bias 
Were the groups similar at the 
start? 
Can’t Tell There is minimal information provided on baseline statistics however age is reported however number of males to 
females is not. Information on baseline characteristics such as age, BMI, IPAP and EPAP settings were provided 
however appears to be a variation in FEV1 SD 11.2 and BMI standard deviation 5.5. The varying distribution of FEV1 and 
BMI may suggest that there is one patient in the Obese category and therefore cannot out that that patient did not have 
a greater effect from increase pressure as patients with higher BMI’s require high pressures to ventilate more efficiently. 
However, this is speculation due to the minimal information on characteristic. 
Aside from the experimental 
intervention were the groups 
equally treated 
Yes  There is no appearance of favourable treatment, patients were all treated as per protocol. 
How large was the treatment 
effect and how precise were the 
estimate of treatment effect 
 P value for all groups P>.05  
Mean between group difference 
PaCO2– 6.4(95% CI -10.9 to 1.8 p value 0.1) 
No difference in sleep quality mean difference -3.0 (95% CI, -10.0 to 3.9, P-value 0.36) 
HCO3 -1.8 (95% CI -3.1 to -0.50 P value 0.013) 
pH 0.025 (0.004 to 0.0046, P -value 0.25) 
paO2 2.5 (-4.7 to 9.8 P value 0.46) 
 
small sample quite large confidence limits, statement calculation to access number needed for clinical significance 
estimate 13 patients. Larger samples would provide more accurate confidence limits. 
Can the results be applied to the 
local population or in your 
context? 
No Small sample, all received high pressure NIV prior to treatment as they were previously set up and therefore exposed to 
NIV prior to treatment. However, patients were in the same GOLD category IV and receiving standard medical therapy 
there is no discussion as to the details of the treatment plan.  
Short duration in terms of follow up unable and may be open performance bias as patients were assessed in laboratory 
environment.  
Unable to assess the long-term effects of the intervention due to the short duration of time. Study also completed in 
Germany and unsure of their practices or guidelines of management and domiciliary NIV. 
 
Were all clinically important 
outcomes considered? 
No No measure of: HRQOL, Lung function post treatment, Exercise capacity, number of exacerbations, leak. 
 
However, provided the short duration of time unable to discuss the effects at length on the listed outcomes.  There is no 
detail of tolerance overnight, and considering this is investigating the effect of sleep, it would be a useful outcome to 
assess the length of time patient was on continuous NIV. 
 









Issue not addressed in the published report. The study protocol seems similar to a previous study completed in 2010 by 
the same author, could be a following study however this is not confirmed. 
Based on the study protocol, the duration of the study completed, the small sample, the design and the dropout rate, the 
results, although, add to the body of knowledge of NIV on sleep there are multiple systematic flaws in the published 
study which may influence the results.  
 
Continued 2 of 3   
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Other considerations of carry over effects, due to cross over designs and to factor in that patients had been exposed to 
NIV previously. Authors address this with and ANOVA however it is currently unknow the long-term effects of NIV and 
although there is a statistical analysis clinically this is difficult to rule out. What is known is that there is an improvement 
on NIV regardless of the pressure given.   
 
They discuss humidification, both nasal and oronasal masks, the oronasal masks are better at coping with high pressure 
ventilation that nasal mask, could be the reason for improved ventilation.  





















Continued 3 of 3   
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Table 20 Critical Appraisal (Dreher et al. 2010) 
 
CASP Criteria for Randomised 




Did the trial address a clearly 
focused issue? 
Yes  Population- Adult, diagnosis of COPD, GOLD stage, IV, stable COPD with chronic hypercapnic respiratory failure, 
albescence of lung pathology neuromuscular, chest wall deformity, Overlapping OHS, bronchiectasis, bronchial 
Carcinoma or post Tb Sequalae, PaCO2> 50mmhg. Patients not included if they were unstable AHRF and with as 
defined as possessing 2 signs, purulent sputum, C-reactive protein >5mg/dl changes in chest x-ray, received NIV in the 
last 3 months or any form of ventilation 
  
Intervention- Hi -NPPV Non- Invasive ventilation 
Comparator- li Non- invasive ventilation 
 
Outcomes- lung function peak inspiratory mouth occlusion pressure, ABG, Exercise capacity 6MWT, Dyspnoea, 
dyspnoea during walking using Borg dyspnoea scale, HRQL using severe respiratory insufficiency questionnaire. 
Pneumotachograph used for ventilatory measurements, compliance as assessed by ventilator count  
 
Physiological and clinical outcomes are reported on  
 
Was the assignment of patients 
to treatments randomised? 
Yes Patients were randomized as reported however no detail on allocation concealment, randomization sequence 
generation. Therefore, risk of biais due to inadequate randomization reporting 
Were all of the patients who 
entered the trial properly 
accounted for at its conclusion? 
Yes   All patients who completed the trial were accounted for, at risk of subject attrition bias due to withdrawal of patients in 
the LI-NPPV to Hi NPPV sequence.  
 
Four patients withdrew >20% of patient population no power calculation was completed. Reasons for withdrawal 
accounted for in flow diagram unlikely to affect results due to power calculation to determine how many participants 
would be required.  
 
Patients were analyzed in both the groups they were in and between group differences were reported. 
2 Due to intolerance of NIV before entering period 2 on li NPPV 
2 During period 1 LI before follow-up due to intolerance of Li NPPV 1, 1 patient stopped at home despite tolerance of Li 
NIV 
 
No details however on follow up of these patients to safeguard from harm.  
 
Due to open labeled study design patients were aware of which treatment sequence they would be on may have 
affected the decision of the patient however due to lack of information on follow up this is purely speculation. 
Continued 1 of 3  
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Were patients, health workers 
and study personnel ‘blind’ to 
treatment? 
No No blinding of researcher, patient or due to nature of the treatment may not be possible to blind researcher however 
possibility to blind those completing the outcome measures as to which sequence.  
 
Due to nature of objective measures for outcome, it is unlikely to affect the result, may have effect however the SRI 
score as QOL been a subjective measure. 
Were the groups similar at the 
start? 
Can’t Tell Minimal information on baseline characteristics, only given because of the patients included in the measurement. 
Therefore, unable to assess, it does however state that they were of GOLD standard IV and FEV1 and the similar 
disease state. 
9 Men and 4 women were accounted for men,  
Sex differences between- women have a reduced FEV1/FVC, increased incidences of women compared to men. 
Aside from the experimental 
intervention were the groups 
equally treated? 
Yes  All patients were exposed to treatments for the same length of time, follow up was completed after 6 weeks. All patients 
had had NIV prior to the investigation on long term Hi NPPV therefore there may have been some carryover effects, no 
evidence of any favourable treatment to one group over the other. 
How large was the treatment 
effect and how precise were the 
estimate of treatment effect? 
 Primary Outcomes nocturnal PaCo2 mean value at 1.00h and 4.00h at follow up visit  
Secondary outcomes, daytime PaCO2 determined at day time PaCO2, HCO3, ling function, PI Max, Dyspnoea after 
6MW, 6MWD SRI scale, and compliance. Analysis of Variance was completed to compare the means with treatment, 
period and randomized sequence effects size estimated as 95% CI tested on a two-side level of 0.05.  
Kolmogorov-Smirnov test to test for variation in means. 
CI are large due to the small sample. T-test was performed using separately for all patients.  
 
Can the results be applied to the 
local population or in your 
context? 
Can’t tell Small sample, of patients who were not naive to NIV. The population included were COPD and due to minimal detail of 
baseline characteristics unable to determine if the patients were similar.  
 
RCT performed in a single centre in Germany, which have their own set of guidelines on the use of domiciliary NIV in 
patients with CHRF further trials would be needed to assess the applicability to the UK health care systems in the UK 
requiring larger samples. 
 
Were all clinically important 
outcomes considered? 
No The scope of the review did not assess for readmission and exacerbations. It would have been beneficial to assess 
pressure settings have an influence of patient’s readmission and exacerbation rate. 
No data was provided on PaO2 and this may be because all patients had a supplementary O2 provided for them may 
have been enough to create a normalized PaO2. It is not discussed as to the effect of different interfaces however 
analysis would shed light on the effect of pressures and efficiency of ventilation, reported some patients had nasal 
masks or oronasal mask, further analysis of which patient had which interface may have shed light into the tolerance of 
NIV 
Are the benefits worth the harms 
and costs? 
Yes   It is likely after a drop-in pressure from 28 to 14 that there would be a significant influence on hypercapnia and a 
reduction of tolerance in patients with COPD and therefore may cause more harm than good. However, it was a 
randomized control trial which adds to the body of knowledge and information of the potential benefits for higher 
pressure NIV. 
As the first study of it kind it has addressed an issue on ventilation and demonstrates the need for further RCT’s in this 
area. 
Appears that the outcome measures were not anything that would be considered as extra analysis and therefore could 
be not subjecting the patient to any extra cost. The length of time taken to establish patient on NIV which they were 
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already established on may be considered as an extra burden on the patient however there is no detail if patient 
received compensation for their time.  
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Table 21 Critical Appraisal (Duiverman et al 2017) 
 
CASP Criteria for Randomised 




Did the trial address a clearly 
focused issue? 
Yes  Patient hypercapnic respiratory failure, absence of lung pathology neuromuscular, chest wall deformity, Overlapping 
OHS, bronchiectasis, bronchial Carcinoma or post Tb Sequalae, pCO2> 50mmhg. Patients not included if they were 
unstable AHRF and with as defined as possessing 2 signs, purulent sputum, C-reactive protein >5mg/dl changes in 
chest x-ray, received NIV in the last 3 months or any form of ventilation 
 
Intervention- Hi -NPPV  
Comparator- li-NPPV 
 
Outcomes- lung function, ABG, polysomnography, overnight oximetry to measure O2 desaturations index (ODI) 
≥4% and number of desaturations per night <90% the largest decrease was recorded, ECG electrooculograms, 
digastric electromyogram, finger probe Sao2, EEG polygraph, total sleep time (TST), sleep efficiency measured by 
TST divided by time spent in bed, arousals were defined as the appearance of EEG of an α wave 3-15 seconds in 
duration.  Sleep measured by 30 second epochs  
 
Physiological outcomes were reported on    
Was the assignment of patients 
to treatments randomised? 
Yes Patients were randomized as reported however no detail on allocation concealment, randomization sequence 
generation. Therefore, risk of bias due to inadequate randomization reporting 
Were all of the patients who 
entered the trial properly 
accounted for at its conclusion? 
Yes   All patients who completed the trial were accounted for, results at risk of subject attrition bias due to withdrawal of 
patients in the LI-NPPV to Hi NPPV sequence.  
 
Four patients withdrew >20% of patient population no power calculation was completed. Reasons for withdrawal 
accounted for in flow diagram unlikely to affect results due to power calculation to determine how many participants 
would be required.  
 
Patients were analyzed in both the groups they were in and between group differences were reported. 
  
1 patient developed decompensated heart failure whilst on the HI-NPPV treatment arm and underwent a procedure  
2 patients developed hypercapnia with PaCO2 above 10Kpa   
 
No details however on follow up of these patients to safeguard from harm.  
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Due to open labeled study design patients were aware of which treatment sequence they would be on may have 
affected the decision of the patient however due to lack of information on follow up this is purely speculation. 
Were patients, health workers 
and study personnel ‘blind’ to 
treatment? 
No No blinding of researcher, patient or due to nature of the treatment may not be possible to blind researcher however 
possibility to blind those completing the outcome measures as to which sequence.  
 
Due to nature of objective measures for outcome, it is unlikely to affect the result, may have effect however the SRI 
score as QOL been a subjective measure. 
Were the groups similar at the 
start? 
No  Noted difference not in stage of disease in COPD, but in variations in cardiac involvement. For this baseline 
characteristics were not averaged in fact they were given independence due to the small sample.  
Aside from the experimental 
intervention were the groups 
equally treated? 
Yes  All patients were exposed to treatments for the same length of time, follow up was completed after 6 weeks. All 
patients had had NIV prior to the investigation on long term Hi NPPV therefore there may have been some 
carryover effects, no evidence of any favourable treatment to one group over the other. 
How large was the treatment 
effect and how precise were the 
estimate of treatment effect? 
 There is some information provided on baseline statistics however age is reported however number of males to 
females is not. Information on baseline characteristics such as age, BMI, IPAP and EPAP settings were provided 
however appears to be a variation in FEV1 SD 11.2 and BMI standard deviation 5.5. The varying distribution of 
FEV1 and BMI may suggest that there is one patient in the Obese category and therefore cannot out that that 
patient did not have a greater effect from increase pressure as patients with higher BMI’s require high pressures to 
ventilate more efficiently. However, this is speculation due to the minimal information on characteristic.  
Large treatment effect as seen may be due to small sample  
 
Mean between group difference was taken for  
PaCO2 -2.8 (95% CI -6.6 to 1.00) 
FEV1 0.00 (95% CI 0.11to 0.010) 
SRI-SS -2.9  (95% CI -8.0-2.0)  
Can the results be applied to the 
local population or in your 
context? 
Can’t tell Small sample, of patients who were not naive to NIV. The population included were COPD and due to minimal detail 
of baseline characteristics unable to determine if the patients were similar.  
 
RCT performed in a single centre in Germany, which have their own set of guidelines on the use of domiciliary NIV 
in patients with CHRF further trials would be needed to assess the applicability to the UK health care systems in the 
UK requiring larger samples. 
 
Were all clinically important 
outcomes considered? 
No The scope of the review did not assess for readmission and exacerbations. It would have been beneficial to assess 
pressure settings have an influence of patient’s readmission and exacerbation rate. 
No data was provided on PaO2 and this may be because all patients had a supplementary O2 provided for them 
may have been enough to create a normalized PaO2. It is not discussed as to the effect of different interfaces 
however analysis would shed light on the effect of pressures and efficiency of ventilation, reported some patients 
had nasal masks or oronasal mask, further analysis of which patient had which interface may have shed light into 
the tolerance of NIV 
Are the benefits worth the harms 
and costs? 
Yes   It is likely after a drop-in pressure from 28 to 14 that there would be a significant influence on hypercapnia and a 
reduction of tolerance in patients with COPD and therefore may cause more harm than good. However, it was a 
randomized control trial which adds to the body of knowledge and information of the potential benefits for higher 
pressure NIV. 
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As the first study of it kind it has addressed an issue on ventilation and demonstrates the need for further RCT’s in 
this area. 
Appears that the outcome measures were not anything that would be considered as extra analysis and therefore 
could be seen as not subjecting the patient to any extra cost. The length of time taken to establish patient on NIV 
which they were already established on may be considered as an extra burden on the patient however there is no 
detail if patient received compensation for their time.  
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Appendix 6 Data Extraction  
Data Extraction Form  
 
Study Details  




Country/ language  
Number of participants at Start of 
Recruitment 
 
Number End of recruitment   




Mean Age   
Number of Males   
Number of females   
Number of recruiting centres   
Where the participants matched at baseline Yes/No/Unsure 
Number of patients randomised   
Details of intervention    Additional details of intervention 
Group  1 2 
Description of Intervention 
  
   




Mean IPAP    
Mean EPAP     
Details of follow up      
Were any other outcome measures taken 
during the study and details of the measures   
 
   Additional outcomes  
Adverse Events recorded If so full details   
Inclusion Criteria  
Exclusion Criteria  
Other Variables to consider  
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Adherence in hours  
 






participants   












 1             
2             
 1             
2             
 1             
2             
 1             
2             
 1              
2             
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2             
 1             
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Appendix 7 Gantt Chart  
  
01/10/2017 30/11/2017 29/01/2018 30/03/2018 29/05/2018 28/07/2018 26/09/2018 25/11/2018
Amendments





Data Collection and Synthesis
Citical Apraisal
Title and abstract screening and selection
Literature Search
Ethical Approval
Protocol Design
